<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmlns="http://hl7.org/fhir" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<id value="4994c34d-193f-405c-a5c0-e5f7f012ab4a" />
	<identifier> 
		<system value="urn:example-org:fda.identifiers"/> 
		<value value="35f23e97-328c-4eb7-8e94-34f478983e891"/> 
	</identifier>
	<type value="message" />
	<entry>
		<fullUrl value="http://hl7.org/fhir/MessageHeader/53497d4b-01f2-46dd-b0ff-5dbe5cfd322e" />
		<resource>
			<MessageHeader>
				<id value="53497d4b-01f2-46dd-b0ff-5dbe5cfd322e" />
				<eventCoding>
					<display value="temp-string of VIB Demo Labeling" />
				</eventCoding>
				<destination>
					<receiver>
						<reference value="Organization/PfizerId" />
					</receiver>
				</destination>
				<sender>
					<reference value="Organization/FDAID" />
				</sender>
				<source>
					<name value="VIB Demo" />
				</source>
				<response> 
				  <identifier> 
					<system value="urn:example-org:docuvera.identifiers"/> 
					<value value="35f23e97-328c-4eb7-8e94-34f478983e89"/> 
				  </identifier>  
				  <code value="ok"/> 
				</response> 
			</MessageHeader>
		</resource>
	</entry>
	<entry>
		<fullUrl value="http://hl7.org/fhir/Task/c21e0d58-af73-498f-8d93-717caf999048" />
		<resource>
			<Task>
				<id value="c21e0d58-af73-498f-8d93-717caf999048" />
				<identifier>
					<system value="http://example.com/system" />
					<value value="c21e0d58-af73-498f-8d93-717caf999048" />
				</identifier>
				<groupIdentifier>
					<system value="http://example.com/system" />
					<value value="NDA 212436" />
				</groupIdentifier>
				<status value="requested" />
				<intent value="order" />
				<code>
					<coding>
						<system value="https://www.accessdata.fda.gov/eCTD-temp" />
						<code value="fdaat1" />
						<display value="New Drug Application (NDA)" />
					</coding>
					<coding>
						<system value="https://www.accessdata.fda.gov/eCTD-temp" />
						<code value="fdast1" />
						<display value="Original Application" />
					</coding>
					<coding>
						<!-- the code used here is used to indicate that this Task is asking for changes to the last label submission -->
						<system value="https://www.accessdata.fda.gov/eCTD-temp" />
						<code value="fdasst7" />
						<display value="Correspondence" />
					</coding>
					<text value="NDA Labeling Initial Submission FDA Correspondence" />
				</code>
				<description value="Please make a change for: Supplemental new drug application (sNDA) to add information to section XX and remove information from section YY" />
				<focus>
					<!-- this is a reference to the initial submission Task in the initialSubmissionBySponsor message -->
					<!-- i4i: change the reference to use full URL -->
					<reference value="https://epi-03.azurewebsites.net/Task/bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
					<!-- adding identifier means the recipient system does not need to do a look-up just to know the Task identifier -->
					<identifier>
						<system value="http://example.com/system" />
						<value value="bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
					</identifier>
				</focus>
				<for>
					<reference value="Organization/PfizerId" />
				</for>
				<requester>
					<reference value="Organization/PfizerId" />
				</requester>
				<requestedPerformer>
					<reference>
						<reference value="Organization/FDAID" />
					</reference>
				</requestedPerformer>
				<owner>
					<reference value="Organization/FDAID" />
				</owner>
				<reason>
					<reference>
						<!-- i4i: change the reference to use full URL -->
						<reference value="https://epi-03.azurewebsites.net/Task/bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
						<!-- adding identifier means the recipient system does not need to do a look-up just to know the Task identifier -->
						<identifier>
							<system value="http://example.com/system" />
							<value value="bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
						</identifier>
					</reference>
				</reason>
				<input>
					<type>
						<coding>
							<system value="http://loinc.org" />
							<code value="34391-3" />
							<display value="FDA product label Human prescription drug label" />
						</coding>
						<text value="FDA product label Human prescription drug label" />
					</type>
					<valueReference>
						<!-- the document bunder this task references contains the comments and modifications made by the HA -->
						<reference value="Bundle/bundle-ibrance75-100-125-d" />
					</valueReference>
				</input>
			</Task>
		</resource>
	</entry>
	<!-- i4i: remove second task entry -->
	<!-- B: Redundant inclusion of the previous Task instance may aid some systems. But we are sending the Task.identifier to reduce the need for lookup	-->

	<entry>
		<fullUrl value="http://hl7.org/fhir/Bundle/bundle-ibrance75-100-125-d" />
		<resource>
			<Bundle >
				<id value="bundle-ibrance75-100-125-d"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
				</meta>
				<language value="en"/>
				<identifier>
					<system value="https://www.fda.gov/"/>
					<value value="ibrance"/>
				</identifier>
				<type value="document"/>
				<timestamp value="2022-09-08T00:00:00Z"/>
				<entry>
					<fullUrl value="http://hl7.org/fhir/Composition/compositionusen"/>
					<resource>
						<Composition>
							<id value="compositionusen"/>
							<meta>
								<versionId value="15"/>
								<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
							</meta>
							<language value="en"/>
							<text>
								<status value="generated"/>
								<div xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">These highlights do not include all the information needed
									to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. <br/>
									<br/>IBRANCE<sup>®</sup> (palbociclib) capsules, for oral use <br/>Initial U.S. Approval: 2015
								</div>
							</text>
							<contained>
								<Binary>
									<id value="ibrance-01"/>
									<contentType value="image/jpg"/>
									<data value="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"/>
								</Binary>
							</contained>
							<!-- extension url="http://hl7.org/fhir">
			<valueReference>
			<reference value="#ibrance-01"/>
			</valueReference>
			</extension -->
							<identifier>
								<system value="https://www.fda.gov/"/>
								<value value="2de9790e-3eb6-49ca-a35b-7b42c569f794"/>
							</identifier>
							<status value="final"/>
							<type>
								<coding>
									<system value="http://loinc.org"/>
									<code value="34391-3"/>
									<display value="FDA product label Human prescription drug label"/>
								</coding>
								<text value="HUMAN PRESCRIPTION DRUG LABEL"/>
							</type>
							<subject>
								<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
							</subject>
							<subject>
								<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
							</subject>
							<subject>
								<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
							</subject>
							<date value="2022-09-08T00:00:00Z"/>
							<author>
								<reference value="Organization/134489525"/>
							</author>
							<title value="Drug Label for IBRANCE (palbociclib) film coated tablets"/>
							<section>
								<title value="Recent Major Changes"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="43683-2"/>
										<display value="FDA package insert Recent major changes section"/>
									</coding>
									<text value="RECENT MAJOR CHANGES SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<table width="100%">
												<colgroup span="2">
													<col width="85%"/>
													<col width="15%"/>
												</colgroup>
												<tbody>
													<tr>
														<td style="text-align: left; text-align: left; ">
															<p>Indications and Usage <a href="S1">(1)</a>
															</p>
														</td>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">12/2022</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; text-align: left; ">
															<p>Dosage and Administration <a href="S2">(2)</a>
															</p>
														</td>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">12/2022</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; text-align: left; ">
															<p>
																<a id="ins01" class="InsertStart"/>Dosage Forms and Strengths <a href="S3">(3)</a><a href="ins01" class="InsertEnd"/>
															</p>
														</td>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">
																<a id="ins02" class="InsertStart"/>02/2025<a href="ins02" class="InsertEnd"/>
															</p>
														</td>
													</tr>
												</tbody>
											</table>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="1 INDICATIONS AND USAGE"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34067-9"/>
										<display value="FDA package insert Indications and usage section"/>
									</coding>
									<text value="INDICATIONS &amp; USAGE SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<p>IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with
												hormone receptor (HR)-positive, human epidermal growth factor receptor 2
												(HER2)-negative advanced or metastatic breast cancer in combination with <a id="ins03" class="InsertStart"/>one or more of the following<a href="ins03" class="InsertEnd"/>:</p>
											<ul>
												<li>an aromatase inhibitor as initial endocrine-based therapy (<a href="S1">1</a>); or</li>
												<li>fulvestrant in patients with disease progression following endocrine therapy.
													(<a href="S1">1</a>)</li>
											</ul>
										</div>
										<div style="narrative">
											<p>IBRANCE is indicated for the treatment of adult patients with hormone receptor
												(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or
												metastatic breast cancer in combination with <a id="ins04" class="InsertStart"/>one or more of the following<a href="ins04" class="InsertEnd"/>:</p>
											<ul>
												<li id="_RefS1">an aromatase inhibitor as initial endocrine-based therapy; or</li>
												<li>fulvestrant in patients with disease progression following endocrine therapy.
												</li>
											</ul>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="2 DOSAGE AND ADMINISTRATION"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34068-7"/>
										<display value="FDA package insert Dosage and administration section"/>
									</coding>
									<text value="DOSAGE &amp; ADMINISTRATION SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<p>IBRANCE capsules are taken orally with food in combination with an aromatase
												inhibitor or fulvestrant. (<a href="S2.2">2</a>)</p>
											<ul>
												<li>Recommended starting dose: 125 mg once daily taken with food for 21 days
													followed by 7 days off treatment. (<a href="S2.1">2.1</a>)</li>
												<li>Dosing interruption and/or dose reductions are recommended based on individual
													safety and tolerability. (<a href="S2.2">2.2</a>)</li>
											</ul>
										</div>
									</div>
								</text>
								<section>
									<title value="2.1 Recommended Dose and Schedule"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for
													21 consecutive days followed by 7 days off treatment to comprise a complete
													cycle of 28 days. IBRANCE should be taken with food <em>[see <a href="S12.3">Clinical Pharmacology (12.3)</a>]</em>.</p>
												<p>Administer the recommended dose of an aromatase inhibitor when given with
													IBRANCE. Please refer to the Full Prescribing Information for the aromatase
													inhibitor being used.</p>
												<p>When given with IBRANCE, the recommended dose of fulvestrant is 500 mg
													administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the
													Full Prescribing Information of fulvestrant.</p>
												<p>Patients should be encouraged to take their dose of IBRANCE at approximately the
													same time each day.</p>
												<p>If the patient vomits or misses a dose, an additional dose should not be taken.
													The next prescribed dose should be taken at the usual time. IBRANCE capsules
													should be swallowed whole (do not chew, crush, or open them prior to
													swallowing). Capsules should not be ingested if they are broken, cracked, or
													otherwise not intact.</p>
												<p>Pre/perimenopausal women treated with the combination IBRANCE plus <span>an
														aromatase inhibitor or </span>fulvestrant therapy should also be treated
													with luteinizing hormone-releasing hormone (LHRH) agonists according to current
													clinical practice standards.</p>
												<p>For men treated with combination IBRANCE plus aromatase inhibitor therapy,
													consider treatment with an LHRH agonist according to current clinical practice
													standards.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="2.2 Dose Modification"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>The recommended dose modifications for adverse reactions are listed in Tables 1,
													2, and 3.</p>
												<table width="70%">
													<caption>Table 1. Recommended Dose Modification for Adverse Reactions</caption>
													<colgroup span="2">
														<col width="38%"/>
														<col width="43%"/>
													</colgroup>
													<thead>
														<tr>
															<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																<strong>Dose Level</strong>
															</td>
															<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																<strong>Dose</strong>
															</td>
														</tr>
													</thead>
													<tbody>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																<p>Recommended starting dose</p>
															</td>
															<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">125 mg/day</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>First dose reduction</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">100 mg/day</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																<p>Second dose reduction</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">75 mg/day</p>
															</td>
														</tr>
													</tbody>
												</table>
												<p>
			If further
													dose reduction below 75 mg/day is required, discontinue.</p>
												<table width="80%">
													<caption>Table 2. Dose Modification and Management – Hematologic Toxicities</caption>
													<colgroup span="2">
														<col width="19%"/>
														<col width="73%"/>
													</colgroup>
													<tfoot>
														<tr>
															<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="2">Grading according to CTCAE 4.0.<br/>CTCAE=Common
																Terminology Criteria for Adverse Events; LLN=lower limit of normal.
															</td>
														</tr>
													</tfoot>
													<tbody>
														<tr>
															<td colspan="2" style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: left; ">
																<p>Monitor complete blood counts prior to the start of IBRANCE
																	therapy and at the beginning of each cycle, as well as on Day 15
																	of the first 2 cycles, and as clinically indicated.<br/>For
																	patients who experience a maximum of Grade 1 or 2 neutropenia in
																	the first 6 cycles, monitor complete blood counts for subsequent
																	cycles every 3 months, prior to the beginning of a cycle and as
																	clinically indicated.</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: center; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>CTCAE Grade</strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>Dose Modifications</strong>
																</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>Grade 1 or 2</p>
															</td>
															<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
																<p>No dose adjustment is required.</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>Grade 3</p>
															</td>
															<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
																<p>
																	<span style="text-decoration: underline; ">Day 1 of
																		cycle</span>:<br/>Withhold IBRANCE, repeat complete blood
																	count monitoring within 1 week. When recovered to Grade ≤2,
																	start the next cycle at the <em>same dose</em>.<br/>
																	<span style="text-decoration: underline; ">Day 15 of first 2
																		cycles</span>:<br/>If Grade 3 on Day 15, continue IBRANCE
																	at current dose to complete cycle and repeat complete blood
																	count on Day 22.<br/>If Grade 4 on Day 22, see dose
																	modification guidelines below.<br/>Consider dose reduction in
																	cases of prolonged (&gt;1 week) recovery from Grade 3
																	neutropenia or recurrent Grade 3 neutropenia on Day 1 of
																	subsequent cycles.</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>Grade 3 neutropenia with fever
																	≥38.5 ºC and/or infection</p>
															</td>
															<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
																<p>
																	<span style="text-decoration: underline; ">At any
																		time</span>:<br/>Withhold IBRANCE until recovery to Grade
																	≤2.<br/>Resume at the <em>next lower dose</em>.</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																<p>Grade 4</p>
															</td>
															<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
																<p>
																	<span style="text-decoration: underline; ">At any
																		time</span>:<br/>Withhold IBRANCE until recovery to Grade
																	≤2.<br/>Resume at the <em>next lower dose</em>.</p>
															</td>
														</tr>
													</tbody>
												</table>
												<p>
			Table
													applies to all hematologic adverse reactions except lymphopenia (unless
													associated with clinical events, e.g., opportunistic infections).</p>
												<p>
			Absolute
													neutrophil count (ANC): Grade 1: ANC &lt; LLN - 1500/mm<sup>3</sup>; Grade 2:
													ANC 1000 - &lt;1500/mm<sup>3</sup>; Grade 3: ANC 500 - &lt;1000/mm<sup>3</sup>;
													Grade 4: ANC &lt;500/mm<sup>3</sup>.</p>
												<table width="70%">
													<caption>Table 3. Dose Modification and Management – Non-Hematologic Toxicities
													</caption>
													<colgroup span="2">
														<col width="36%"/>
														<col width="45%"/>
													</colgroup>
													<thead>
														<tr>
															<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																<strong>CTCAE Grade</strong>
															</td>
															<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																<strong>Dose Modifications</strong>
															</td>
														</tr>
													</thead>
													<tfoot>
														<tr>
															<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="2">Grading according to CTCAE 4.0.<br/>CTCAE=Common
																Terminology Criteria for Adverse Events.</td>
														</tr>
													</tfoot>
													<tbody>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																<p>Grade 1 or 2</p>
															</td>
															<td style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																<p>No dose adjustment is required.</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																<p>Grade ≥3 non-hematologic toxicity (if persisting despite optimal
																	medical treatment)</p>
															</td>
															<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
																<p>Withhold until symptoms resolve to:</p>
																<ul>
																	<li>Grade ≤1;</li>
																	<li>Grade ≤2 (if not considered a safety risk for the patient)
																	</li>
																</ul>
																<p>Resume at the <em>next lower dose</em>.</p>
															</td>
														</tr>
													</tbody>
												</table>
												<p>Permanently discontinue IBRANCE in patients with severe interstitial lung disease
													(ILD)/pneumonitis.</p>
												<p>Refer to the Full Prescribing Information for coadministered endocrine therapy
													dose adjustment guidelines in the event of toxicity and other relevant safety
													information or contraindications.</p>
											</div>
										</div>
									</text>
									<section>
										<title value="Dose Modifications for Use With Strong CYP3A Inhibitors"/>
										<code>
											<coding>
												<system value="http://loinc.org"/>
												<code value="42229-5"/>
												<display value="FDA package insert Structured patient labelling unclassified section"/>
											</coding>
											<text value="SPL UNCLASSIFIED SECTION"/>
										</code>
										<text>
											<status value="additional"/>
											<div xmlns="http://www.w3.org/1999/xhtml">
												<div style="narrative">
													<p>Avoid concomitant use of strong CYP3A inhibitors and consider an alternative
														concomitant medication with no or minimal CYP3A inhibition. If patients must
														be coadministered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg
														once daily. If the strong inhibitor is discontinued, increase the IBRANCE
														dose (after 3 to 5 half-lives of the inhibitor) to the dose used prior to
														the initiation of the strong CYP3A inhibitor <em>[see <a href="S7.1">Drug
																Interactions (7.1)</a> and <a href="S12.3">Clinical
																Pharmacology (12.3)</a>].</em>
													</p>
												</div>
											</div>
										</text>
									</section>
									<section>
										<title value="Dose Modifications for Hepatic Impairment"/>
										<code>
											<coding>
												<system value="http://loinc.org"/>
												<code value="42229-5"/>
												<display value="FDA package insert Structured patient labelling unclassified section"/>
											</coding>
											<text value="SPL UNCLASSIFIED SECTION"/>
										</code>
										<text>
											<status value="additional"/>
											<div xmlns="http://www.w3.org/1999/xhtml">
												<div style="narrative">
													<p>No dose adjustment is required for patients with mild or moderate hepatic
														impairment (Child-Pugh classes A and B). For patients with severe hepatic
														impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg
														once daily for 21 consecutive days followed by 7 days off treatment to
														comprise a complete cycle of 28 days <em>[see <a href="S8.6">Use in
																Specific Populations (8.6)</a> and <a href="S12.3">Clinical
																Pharmacology (12.3)</a>].</em>
													</p>
												</div>
											</div>
										</text>
									</section>
								</section>
							</section>
							<section>
								<title value="3 DOSAGE FORMS AND STRENGTHS"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="43678-2"/>
										<display value="FDA package insert Dosage forms and strengths section"/>
									</coding>
									<text value="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<p>Capsules: 125 mg<a id="del02" class="DeleteStart"/>, 100 mg,<a href="del02" class="DeleteEnd"/> and 75 mg. (<a href="S3">3</a>)</p>
										</div>
										<div style="narrative">
											<p>125 mg capsules: opaque, hard gelatin capsules, size 0, with caramel cap and body,
												printed with white ink "Pfizer" on the cap, "PBC 125" on the body.</p>
											<p>
												<a id="del01" class="DeleteStart"/>100 mg capsules: opaque,
													hard gelatin capsules, size 1, with caramel cap and light
													orange body, printed with white ink "Pfizer" on the cap, "PBC 100" on the
													body.<a href="del01" class="DeleteEnd"/>
											</p>
											<p>75 mg capsules: opaque, hard gelatin capsules, size 2, with light orange cap and
												body, printed with white ink "Pfizer" on the cap, "PBC 75" on the body.</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="4 CONTRAINDICATIONS"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34070-3"/>
										<display value="FDA package insert Contraindications section"/>
									</coding>
									<text value="CONTRAINDICATIONS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<p>None. (<a href="S4">4</a>)</p>
										</div>
										<div style="narrative">
											<p>None.</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="5 WARNINGS AND PRECAUTIONS"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="43685-7"/>
										<display value="FDA package insert Warnings and precautions section"/>
									</coding>
									<text value="WARNINGS AND PRECAUTIONS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<ul>
												<li>Neutropenia: Monitor complete blood count prior to start of IBRANCE therapy and
													at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and
													as clinically indicated. (<a href="S2.2">2.2</a>, <a href="S5.1">5.1</a>)</li>
												<li>Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of
													ILD/pneumonitis have been reported. Monitor for pulmonary symptoms of
													ILD/pneumonitis. Interrupt IBRANCE immediately in patients with suspected
													ILD/pneumonitis. Permanently discontinue IBRANCE if severe ILD/pneumonitis
													occurs. (<a href="S5.2">5.2</a>)</li>
												<li>Embryo-Fetal Toxicity: IBRANCE can cause fetal harm. Advise patients of
													potential risk to a fetus and to use effective contraception. (<a href="S5.3">5.3</a>, <a href="S8.1">8.1</a>, <a href="S8.3">8.3</a>)</li>
											</ul>
										</div>
									</div>
								</text>
								<section>
									<title value="5.1 Neutropenia"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Neutropenia was the most frequently reported adverse reaction in PALOMA-2 with an
													incidence of 80% and PALOMA-3 with an incidence of 83%. A Grade ≥3 decrease in
													neutrophil counts was reported in 66% of patients receiving IBRANCE plus
													letrozole in PALOMA-2 and 66% of patients receiving IBRANCE plus fulvestrant in
													PALOMA-3. In PALOMA-2 and PALOMA-3, the median time to first episode of any
													grade neutropenia was 15 days and the median duration of Grade ≥3 neutropenia
													was 7 days <em>[see <a href="S6.1">Adverse Reactions (6.1)</a>]</em>.
												</p>
												<p>Monitor complete blood counts prior to starting IBRANCE therapy and at the
													beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as
													clinically indicated. Dose interruption, dose reduction, or delay in starting
													treatment cycles is recommended for patients who develop Grade 3 or 4
													neutropenia <em>[see <a href="S2.2">Dosage and Administration
															(2.2)</a>]</em>. </p>
												<p>Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE
													across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed
													in PALOMA-3. Physicians should inform patients to promptly report any episodes
													of fever <em>[see <a href="S17">Patient Counseling Information
															(17)</a>]</em>. </p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="5.2 Interstitial Lung Disease (ILD)/Pneumonitis"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or
													pneumonitis can occur in patients treated with cyclin-dependent kinase 4/6
													(CDK4/6) inhibitors, including IBRANCE when taken in combination with endocrine
													therapy.</p>
												<p>Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% of IBRANCE-treated
													patients had ILD/pneumonitis of any grade, 0.1% had Grade 3 or 4 and no fatal
													cases were reported. Additional cases of ILD/pneumonitis have been observed in
													the postmarketing setting, with fatalities reported <em>[see <a href="S6.2">Adverse Reactions (6.2)</a>]</em>.</p>
												<p>Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g.
													hypoxia, cough, dyspnea). In patients who have new or worsening respiratory
													symptoms and are suspected to have developed pneumonitis, interrupt IBRANCE
													immediately and evaluate the patient. Permanently discontinue IBRANCE in
													patients with severe ILD or pneumonitis <em>[see <a href="S2.2">Dosage
															and Administration (2.2)</a>]</em>.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="5.3 Embryo-Fetal Toxicity"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Based on findings from animal studies and its mechanism of action, IBRANCE can
													cause fetal harm when administered to a pregnant woman. In animal reproduction
													studies, administration of palbociclib to pregnant rats and rabbits during
													organogenesis resulted in embryo-fetal toxicity at maternal exposures that were
													≥4 times the human clinical exposure based on area under the curve (AUC). Advise
													pregnant women of the potential risk to a fetus. Advise females of reproductive
													potential to use effective contraception during treatment with IBRANCE and for
													at least 3 weeks after the last dose <em>[see <a href="S8.1">Use in
															Specific Populations (8.1</a> and <a href="S8.3">8.3)</a> and <a href="S12.1">Clinical Pharmacology (12.1)</a>]</em>. </p>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="6 ADVERSE REACTIONS"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34084-4"/>
										<display value="FDA package insert Adverse reactions section"/>
									</coding>
									<text value="ADVERSE REACTIONS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<p>Most common adverse reactions (incidence ≥10%) were neutropenia, infections,
												leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea,
												thrombocytopenia, rash, vomiting, decreased appetite, asthenia, and pyrexia. (<a href="S6.2">6</a>)</p>
											<p>
												<strong>To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985
													or FDA at 1-800-FDA-1088 or <a href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</strong>
											</p>
										</div>
										<div style="narrative">
											<p>The following clinically significant adverse reactions are described elsewhere in the
												labeling:</p>
											<ul>
												<li>Neutropenia <em>[see <a href="S5.1">Warnings and Precautions
															(5.1)</a>]</em>
												</li>
												<li>ILD/Pneumonitis <em>[see <a href="S5.2">Warnings and Precautions
															(5.2)</a>]</em>
												</li>
											</ul>
										</div>
									</div>
								</text>
								<section>
									<title value="6.1 Clinical Studies Experience"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Because clinical trials are conducted under varying conditions, the adverse
													reaction rates observed cannot be directly compared to rates in other trials and
													may not reflect the rates observed in clinical practice.</p>
											</div>
										</div>
									</text>
									<section>
										<title value="PALOMA-2: IBRANCE plus
															Letrozole"/>
										<code>
											<coding>
												<system value="http://loinc.org"/>
												<code value="42229-5"/>
												<display value="FDA package insert Structured patient labelling unclassified section"/>
											</coding>
											<text value="SPL UNCLASSIFIED SECTION"/>
										</code>
										<text>
											<status value="additional"/>
											<div xmlns="http://www.w3.org/1999/xhtml">
												<div style="narrative">
													<p>
														<strong>Patients with estrogen receptor (ER)-positive, HER2-negative
																advanced or metastatic breast cancer for initial endocrine based
																therapy</strong>
													</p>
													<p>The safety of IBRANCE (125 mg/day) plus letrozole (2.5 mg/day) versus
															placebo plus letrozole was evaluated in PALOMA-2. The data described
															below reflect exposure to IBRANCE in 444 out of 666 patients with
															ER-positive, HER2-negative advanced breast cancer who received at least
															1 dose of IBRANCE plus letrozole in PALOMA-2. The median duration of
															treatment for IBRANCE plus letrozole was 19.8 months while the median
															duration of treatment for placebo plus letrozole arm was 13.8 months.
														</p>
													<p>Dose reductions due to an adverse reaction of any grade occurred in 36%
															of patients receiving IBRANCE plus letrozole. No dose reduction was
															allowed for letrozole in PALOMA-2.</p>
													<p>Permanent discontinuation associated with an adverse reaction occurred in
															43 of 444 (9.7%) patients receiving IBRANCE plus letrozole and in 13 of
															222 (5.9%) patients receiving placebo plus letrozole. Adverse reactions
															leading to permanent discontinuation for patients receiving IBRANCE plus
															letrozole included neutropenia (1.1%) and alanine aminotransferase
															increase (0.7%).</p>
													<p>The most common adverse reactions (≥10%) of any grade reported in
															patients in the IBRANCE plus letrozole arm by descending frequency were
															neutropenia, infections, leukopenia, fatigue, nausea, alopecia,
															stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia,
															vomiting, decreased appetite, dry skin, pyrexia, and dysgeusia.</p>
													<p>The most frequently reported Grade ≥3 adverse reactions (≥5%) in patients
															receiving IBRANCE plus letrozole by descending frequency were
															neutropenia, leukopenia, infections, and anemia.</p>
													<p>Adverse reactions (≥10%) reported in patients who received IBRANCE plus
															letrozole or placebo plus letrozole in PALOMA-2 are listed in Table 4.
														</p>
													<table width="90%">
														<caption>Table 4. Adverse Reactions (≥10%) in PALOMA-2</caption>
														<colgroup span="7">
															<col width="33%"/>
															<col width="12%"/>
															<col width="10%"/>
															<col width="12%"/>
															<col width="11%"/>
															<col width="11%"/>
															<col width="11%"/>
														</colgroup>
														<thead>
															<tr>
																<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>IBRANCE plus
																			Letrozole</strong>
																	<br/>
																	<strong>(N=444)</strong>
																</td>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Placebo plus
																			Letrozole</strong>
																	<br/>
																	<strong>(N=222)</strong>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; vertical-align: top; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Adverse Reaction</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																	<br/>
																	<strong>%</strong>
																</td>
															</tr>
														</thead>
														<tfoot>
															<tr>
																<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">Grading according to CTCAE
																		4.0.<br/>CTCAE=Common Terminology Criteria for Adverse
																		Events; N=number of patients; N/A=not applicable;</td>
															</tr>
														</tfoot>
														<tbody>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																	<p>Infections and infestations</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Infections</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">60</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">6</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">42</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">3</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Blood and lymphatic system disorders</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Neutropenia</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">80</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">56</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">10</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">6</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Leukopenia</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">39</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">24</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Anemia</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">24</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">5</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">&lt;1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">9</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Thrombocytopenia</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">16</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">&lt;1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Metabolism and nutrition disorders</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Decreased appetite</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">15</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">9</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Nervous system disorders</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Dysgeusia</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">10</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">5</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Gastrointestinal disorders</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Stomatitis</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">30</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">14</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Nausea</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">35</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">&lt;1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">26</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Diarrhea</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">26</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">19</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Vomiting</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">16</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">17</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Skin and subcutaneous tissue disorders</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Alopecia</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">33</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">16</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Rash</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">18</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">12</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Dry skin</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">12</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">6</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>General disorders and administration site conditions</p>
																</td>
																<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Fatigue</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">37</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">28</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Asthenia</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">17</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">12</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																	<p>  Pyrexia</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">12</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">9</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
														</tbody>
													</table>
													<p>
			Infections includes all
															reported preferred terms (PTs) that are part of the System Organ Class
															Infections and infestations.</p>
													<p>
			Most
															common infections (≥1%) include: nasopharyngitis, upper respiratory
															tract infection, urinary tract infection, oral herpes, sinusitis,
															rhinitis, bronchitis, influenza, pneumonia, gastroenteritis,
															conjunctivitis, herpes zoster, pharyngitis, cellulitis, cystitis, lower
															respiratory tract infection, tooth infection, gingivitis, skin
															infection, gastroenteritis viral, respiratory tract infection,
															respiratory tract infection viral, and folliculitis.</p>
													<p>
			Stomatitis includes:
															aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth
															ulceration, mucosal inflammation, oral pain, oral discomfort,
															oropharyngeal pain, and stomatitis.</p>
													<p>
			Grade 1 events – 30%;
															Grade 2 events – 3%.</p>
													<p>
			Grade 1 events – 15%;
															Grade 2 events – 1%.</p>
													<p>
			Rash
															includes the following PTs: rash, rash maculo-papular, rash pruritic,
															rash erythematous, rash papular, dermatitis, dermatitis acneiform, and
															toxic skin eruption.</p>
													<p>Additional adverse reactions occurring at an overall incidence of
															&lt;10.0% of patients receiving IBRANCE plus letrozole in PALOMA-2
															included alanine aminotransferase increased (9.9%), aspartate
															aminotransferase increased (9.7%), epistaxis (9.2%), lacrimation
															increased (5.6%), dry eye (4.1%), vision blurred (3.6%), and febrile
															neutropenia (2.5%).</p>
													<table width="75%">
														<caption>Table 5. Laboratory Abnormalities in PALOMA-2</caption>
														<colgroup span="7">
															<col width="23%"/>
															<col width="11%"/>
															<col width="10%"/>
															<col width="11%"/>
															<col width="11%"/>
															<col width="10%"/>
															<col width="10%"/>
														</colgroup>
														<thead>
															<tr>
																<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>IBRANCE plus
																			Letrozole</strong>
																	<br/>
																	<strong>(N=444)</strong>
																</td>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Placebo plus
																			Letrozole</strong>
																	<br/>
																	<strong>(N=222)</strong>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; vertical-align: top; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Laboratory Abnormality</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																	<br/>
																	<strong>%</strong>
																</td>
															</tr>
														</thead>
														<tfoot>
															<tr>
																<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">N=number of patients; WBC=white blood cells.
																	</td>
															</tr>
														</tfoot>
														<tbody>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																	<p>WBC decreased</p>
																</td>
																<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">97</p>
																</td>
																<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">35</p>
																</td>
																<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">25</p>
																</td>
																<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Neutrophils decreased</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">95</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">56</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">12</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">20</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Anemia</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">78</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">6</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">42</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Platelets decreased</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">63</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">14</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Aspartate aminotransferase increased</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">52</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">3</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">34</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																	<p>Alanine aminotransferase increased</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">43</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">&lt;1</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">30</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
														</tbody>
													</table>
												</div>
											</div>
										</text>
									</section>
									<section>
										<title value="PALOMA-3: IBRANCE plus
															Fulvestrant"/>
										<code>
											<coding>
												<system value="http://loinc.org"/>
												<code value="42229-5"/>
												<display value="FDA package insert Structured patient labelling unclassified section"/>
											</coding>
											<text value="SPL UNCLASSIFIED SECTION"/>
										</code>
										<text>
											<status value="additional"/>
											<div xmlns="http://www.w3.org/1999/xhtml">
												<div style="narrative">
													<p>
														<strong>Patients with HR-positive, HER2-negative advanced or metastatic
																breast cancer who have had disease progression on or after prior
																adjuvant or metastatic endocrine therapy</strong>
													</p>
													<p>The safety of IBRANCE (125 mg/day) plus fulvestrant (500 mg) versus
															placebo plus fulvestrant was evaluated in PALOMA-3. The data described
															below reflect exposure to IBRANCE in 345 out of 517 patients with
															HR-positive, HER2-negative advanced or metastatic breast cancer who
															received at least 1 dose of IBRANCE plus fulvestrant in PALOMA-3. The
															median duration of treatment for IBRANCE plus fulvestrant was 10.8
															months while the median duration of treatment for placebo plus
															fulvestrant arm was 4.8 months.</p>
													<p>Dose reductions due to an adverse reaction of any grade occurred in 36%
															of patients receiving IBRANCE plus fulvestrant. No dose reduction was
															allowed for fulvestrant in PALOMA-3.</p>
													<p>Permanent discontinuation associated with an adverse reaction occurred in
															19 of 345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6 of
															172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions
															leading to discontinuation for those patients receiving IBRANCE plus
															fulvestrant included fatigue (0.6%), infections (0.6%), and
															thrombocytopenia (0.6%).</p>
													<p>The most common adverse reactions (≥10%) of any grade reported in
															patients in the IBRANCE plus fulvestrant arm by descending frequency
															were neutropenia, leukopenia, infections, fatigue, nausea, anemia,
															stomatitis, diarrhea, thrombocytopenia, vomiting, alopecia, rash,
															decreased appetite, and pyrexia.</p>
													<p>The most frequently reported Grade ≥3 adverse reactions (≥5%) in patients
															receiving IBRANCE plus fulvestrant in descending frequency were
															neutropenia and leukopenia.</p>
													<p>Adverse reactions (≥10%) reported in patients who received IBRANCE plus
															fulvestrant or placebo plus fulvestrant in PALOMA-3 are listed in Table
															6.</p>
													<table width="85%">
														<caption>Table 6. Adverse Reactions (≥10%) in PALOMA-3</caption>
														<colgroup span="7">
															<col width="23%"/>
															<col width="19%"/>
															<col width="16%"/>
															<col width="10%"/>
															<col width="11%"/>
															<col width="10%"/>
															<col width="10%"/>
														</colgroup>
														<thead>
															<tr>
																<td rowspan="3" style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Adverse Reaction</strong>
																</td>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>IBRANCE plus
																			Fulvestrant</strong>
																	<br/>
																	<strong>(N=345)</strong>
																</td>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Placebo plus
																			Fulvestrant</strong>
																	<br/>
																	<strong>(N=172)</strong>
																</td>
															</tr>
															<tr>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																</td>
															</tr>
															<tr>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>%</strong>
																</td>
															</tr>
														</thead>
														<tfoot>
															<tr>
																<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">Grading according to CTCAE
																		4.0.<br/>CTCAE=Common Terminology Criteria for Adverse
																		Events; N=number of patients; N/A=not applicable.</td>
															</tr>
														</tfoot>
														<tbody>
															<tr>
																<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																	<p>Infections and infestations</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Infections</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">47</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">3</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">31</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">3</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Blood and lymphatic system disorders</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Neutropenia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">83</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">55</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">11</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">4</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Leukopenia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">53</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">30</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">5</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Anemia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">30</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">4</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">13</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Thrombocytopenia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">23</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Metabolism and nutrition disorders</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Decreased appetite</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">16</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">8</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Gastrointestinal disorders</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Nausea</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">34</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">28</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Stomatitis</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">28</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">13</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Diarrhea</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">24</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">19</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Vomiting</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">19</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">15</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Skin and subcutaneous tissue disorders</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Alopecia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">18</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">6</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">N/A</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>  Rash</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">17</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">6</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>General disorders and administration site conditions</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
																	<p>  Fatigue</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">41</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">29</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																	<p>  Pyrexia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">13</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">&lt;1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">5</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
														</tbody>
													</table>
													<p>
			Infections includes all
															reported preferred terms (PTs) that are part of the System Organ Class
															Infections and infestations.</p>
													<p>
			Most
															common infections (≥1%) include: nasopharyngitis, upper respiratory
															infection, urinary tract infection, bronchitis, rhinitis, influenza,
															conjunctivitis, sinusitis, pneumonia, cystitis, oral herpes, respiratory
															tract infection, gastroenteritis, tooth infection, pharyngitis, eye
															infection, herpes simplex, and paronychia.</p>
													<p>
			Stomatitis includes:
															aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth
															ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort,
															oropharyngeal pain, stomatitis.</p>
													<p>
			Grade 1 events – 17%;
															Grade 2 events – 1%.</p>
													<p>
			Grade 1 events – 6%.
														</p>
													<p>
			Rash
															includes: rash, rash maculo-papular, rash pruritic, rash erythematous,
															rash papular, dermatitis, dermatitis acneiform, toxic skin eruption.</p>
													<p>Additional adverse reactions occurring at an overall incidence of
															&lt;10.0% of patients receiving IBRANCE plus fulvestrant in PALOMA-3
															included asthenia (7.5%), aspartate aminotransferase increased (7.5%),
															dysgeusia (6.7%), epistaxis (6.7%), lacrimation increased (6.4%), dry
															skin (6.1%), alanine aminotransferase increased (5.8%), vision blurred
															(5.8%), dry eye (3.8%), and febrile neutropenia (0.9%).</p>
													<table width="80%">
														<caption>Table 7. Laboratory Abnormalities in PALOMA-3</caption>
														<colgroup span="7">
															<col width="21%"/>
															<col width="17%"/>
															<col width="14%"/>
															<col width="10%"/>
															<col width="10%"/>
															<col width="10%"/>
															<col width="9%"/>
														</colgroup>
														<thead>
															<tr>
																<td rowspan="2" style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Laboratory Abnormality</strong>
																</td>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>IBRANCE plus
																			Fulvestrant</strong>
																	<br/>
																	<strong>(N=345)</strong>
																</td>
																<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Placebo plus
																			Fulvestrant</strong>
																	<br/>
																	<strong>(N=172)</strong>
																</td>
															</tr>
															<tr>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>All Grades</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 3</strong>
																	<br/>
																	<strong>%</strong>
																</td>
																<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
																	<strong>Grade 4</strong>
																	<br/>
																	<strong>%</strong>
																</td>
															</tr>
														</thead>
														<tfoot>
															<tr>
																<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">N=number of patients; WBC=white blood cells.
																	</td>
															</tr>
														</tfoot>
														<tbody>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																	<p>WBC decreased</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">99</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">45</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">26</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Neutrophils decreased</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">96</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">56</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">11</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">14</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Anemia</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">78</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">3</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">40</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Platelets decreased</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">62</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">1</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">10</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																	<p>Aspartate aminotransferase increased </p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">43</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">4</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">48</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">4</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
															<tr>
																<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																	<p>Alanine aminotransferase increased</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">36</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">2</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">34</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
																<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																	<p style="text-align: center; ">0</p>
																</td>
															</tr>
														</tbody>
													</table>
												</div>
											</div>
										</text>
									</section>
								</section>
								<section>
									<title value="6.2 Postmarketing Experience"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>The following adverse reactions have been identified during post-approval use of
													IBRANCE. Because these reactions are reported voluntarily from a population of
													uncertain size, it is not always possible to reliably estimate their frequency
													or establish a causal relationship to drug exposure.</p>
												<p>
													<em>Respiratory Disorders</em>: Interstitial lung disease (ILD)/non-infectious
													pneumonitis</p>
												<p>
													<em>Skin and Subcutaneous Tissue Disorders:</em> Palmar-plantar
													erythrodysesthesia syndrome (PPES)</p>
												<p style="text-decoration: underline; ">
													<strong>Male patients with HR-positive,
															HER2-negative advanced or metastatic breast cancer</strong>
												</p>
												<p>Based on limited data from postmarketing reports and electronic health
														records, the safety profile for men treated with IBRANCE is consistent with
														the safety profile in women treated with IBRANCE.</p>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="7 DRUG INTERACTIONS"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34073-7"/>
										<display value="FDA package insert Drug interactions section"/>
									</coding>
									<text value="DRUG INTERACTIONS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<ul>
												<li>CYP3A Inhibitors: Avoid concurrent use of IBRANCE with strong CYP3A inhibitors.
													If the strong inhibitor cannot be avoided, reduce the IBRANCE dose. (<a href="S2.2">2.2</a>, <a href="S7.1">7.1</a>) </li>
												<li>CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (<a href="S7.2">7.2</a>)</li>
												<li>CYP3A Substrates: The dose of sensitive CYP3A4 substrates with narrow
													therapeutic indices may need to be reduced when given concurrently with IBRANCE.
													(<a href="S7.3">7.3</a>)</li>
											</ul>
										</div>
										<div style="narrative">
											<p>Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme
												SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A.</p>
										</div>
									</div>
								</text>
								<section>
									<title value="7.1 Agents That May Increase Palbociclib Plasma Concentrations"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>
													<strong>Effect of CYP3A Inhibitors</strong>
												</p>
												<p>Coadministration of a strong CYP3A inhibitor (itraconazole) increased the
														plasma exposure of palbociclib in healthy subjects by 87%. Avoid concomitant
														use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir,
														itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir,
														posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and
														voriconazole). Avoid grapefruit or grapefruit juice during IBRANCE
														treatment. If coadministration of IBRANCE with a strong CYP3A inhibitor
														cannot be avoided, reduce the dose of IBRANCE <em>[see <a href="S2.2">Dosage and Administration (2.2)</a> and <a href="S12.3">Clinical Pharmacology (12.3)</a>]</em>.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="7.2 Agents That May Decrease Palbociclib Plasma Concentrations"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>
													<strong>Effect of CYP3A Inducers</strong>
												</p>
												<p>Coadministration of a strong CYP3A inducer (rifampin) decreased the plasma
														exposure of palbociclib in healthy subjects by 85%. Avoid concomitant use of
														strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine,
														enzalutamide, and St John's Wort) <em>[see <a href="S12.3">Clinical
																Pharmacology (12.3)</a>]</em>.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="7.3 Drugs That May Have Their Plasma Concentrations Altered by Palbociclib"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Coadministration of midazolam with multiple doses of IBRANCE increased the
													midazolam plasma exposure by 61%, in healthy subjects, compared to
													administration of midazolam alone. The dose of the sensitive CYP3A substrate
													with a narrow therapeutic index (e.g., alfentanil, cyclosporine,
													dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine,
													sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its
													exposure <em>[see <a href="S12.3">Clinical Pharmacology (12.3)</a>]</em>.
												</p>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="8 USE IN SPECIFIC POPULATIONS"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="43684-0"/>
										<display value="FDA package insert Use in specific populations section"/>
									</coding>
									<text value="USE IN SPECIFIC POPULATIONS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="highlight">
											<ul>
												<li>Lactation: Advise not to breastfeed. (<a href="S8.2">8.2</a>)</li>
											</ul>
										</div>
									</div>
								</text>
								<section>
									<title value="8.1 Pregnancy"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42228-7"/>
											<display value="FDA package insert Pregnancy section"/>
										</coding>
										<text value="PREGNANCY SECTION"/>
									</code>
									<section>
										<title value="Risk Summary"/>
										<code>
											<coding>
												<system value="http://loinc.org"/>
												<code value="42229-5"/>
												<display value="FDA package insert Structured patient labelling unclassified section"/>
											</coding>
											<text value="SPL UNCLASSIFIED SECTION"/>
										</code>
										<text>
											<status value="additional"/>
											<div xmlns="http://www.w3.org/1999/xhtml">
												<div style="narrative">
													<p>Based on findings from animal studies and its mechanism of action, IBRANCE
														can cause fetal harm when administered to a pregnant woman <em>[see <a href="S12.1">Clinical Pharmacology (12.1)</a>]</em>. There
														are no available data in pregnant women to inform the drug-associated risk.
														In animal reproduction studies, administration of palbociclib to pregnant
														rats and rabbits during organogenesis resulted in embryo-fetal toxicity at
														maternal exposures that were ≥4 times the human clinical exposure based on
														AUC. Advise pregnant women of the potential risk
														to a fetus.</p>
													<p>The estimated background risk of major birth defects and miscarriage for the
														indicated population is unknown. In the U.S. general population, the
														estimated background risk of major birth defects and miscarriage in
														clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.</p>
												</div>
											</div>
										</text>
									</section>
									<section>
										<title value="Data"/>
										<code>
											<coding>
												<system value="http://loinc.org"/>
												<code value="42229-5"/>
												<display value="FDA package insert Structured patient labelling unclassified section"/>
											</coding>
											<text value="SPL UNCLASSIFIED SECTION"/>
										</code>
										<text>
											<status value="additional"/>
											<div xmlns="http://www.w3.org/1999/xhtml">
												<div style="narrative">
													<p style="text-decoration: underline; ">Animal Data</p>
													<p>In a fertility and early embryonic development study in female rats,
															palbociclib was administered orally for 15 days before mating through to
															Day 7 of pregnancy, which did not cause embryo toxicity at doses up to
															300 mg/kg/day with maternal systemic exposures approximately 4 times the
															human exposure (AUC) at the recommended dose.</p>
													<p>In embryo-fetal development studies in rats and rabbits, pregnant animals
															received oral doses of palbociclib up to 300 mg/kg/day and 20 mg/kg/day,
															respectively, during the period of organogenesis. The maternally toxic
															dose of 300 mg/kg/day was fetotoxic in rats, resulting in reduced fetal
															body weights. At doses ≥100 mg/kg/day in rats, there was an increased
															incidence of a skeletal variation (increased incidence of a rib present
															at the seventh cervical vertebra). At the maternally toxic dose of 20
															mg/kg/day in rabbits, there was an increased incidence of skeletal
															variations, including small phalanges in the forelimb. At 300 mg/kg/day
															in rats and 20 mg/kg/day in rabbits, the maternal systemic exposures
															were approximately 4 and 9 times the human exposure (AUC) at the
															recommended dose, respectively.</p>
													<p>CDK4/6 double knockout mice have been reported to die in late stages of
															fetal development (gestation Day 14.5 until birth) due to severe anemia.
															However, knockout mouse data may not be predictive of effects in humans
															due to differences in degree of target inhibition.</p>
												</div>
											</div>
										</text>
									</section>
								</section>
								<section>
									<title value="8.2 Lactation"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="77290-5"/>
											<display value="FDA package insert Lactation"/>
										</coding>
										<text value="LACTATION SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>
													<strong>Risk Summary</strong>
												</p>
												<p>There is no information regarding the presence of palbociclib in human milk,
														its effects on milk production, or the breastfed infant. Because of the
														potential for serious adverse reactions in breastfed infants from IBRANCE,
														advise a lactating woman not to breastfeed during treatment with IBRANCE and
														for 3 weeks after the last dose.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="8.3 Females and Males of Reproductive Potential"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="77291-3"/>
											<display value="FDA package insert Females and males reproductive potential"/>
										</coding>
										<text value="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>
													<strong>Pregnancy Testing</strong>
												</p>
												<p>Based on animal studies, IBRANCE can cause fetal harm when administered to a
														pregnant woman <em>[see <a href="S8.1">Use in Specific Populations
																(8.1)]</a>. </em>Females of reproductive potential should have a
														pregnancy test prior to starting treatment with IBRANCE.</p>
												<p>
													<strong>Contraception</strong>
												</p>
												<p style="text-decoration: underline; ">Females</p>
												<p>IBRANCE can cause fetal harm when administered to a pregnant woman
															<em>[see <a href="S8.1">Use in Specific Populations
																	(8.1)</a>]</em>. Advise females of reproductive potential to use
															effective contraception during treatment with IBRANCE and for at least 3
															weeks after the last dose.
														</p>
												<p style="text-decoration: underline; ">Males</p>
												<p>Because of the potential for genotoxicity, advise male patients with
															female partners of reproductive potential to use effective contraception
															during treatment with IBRANCE and for 3 months after the last dose
															<em>[see <a href="S13.1">Nonclinical Toxicology (13.1)</a>]</em>.
														</p>
												<p>
													<strong>Infertility</strong>
												</p>
												<p style="text-decoration: underline; ">Males</p>
												<p>Based on animal studies, IBRANCE may impair fertility in males of
															reproductive potential <em>[see <a href="S13.1">Nonclinical
																	Toxicology (13.1)</a>]</em>.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="8.4 Pediatric Use"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="34081-0"/>
											<display value="FDA package insert Pediatric use section"/>
										</coding>
										<text value="PEDIATRIC USE SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>The safety and efficacy of IBRANCE in pediatric patients have not been studied.
												</p>
												<p>Altered glucose metabolism (glycosuria, hyperglycemia, decreased insulin)
													associated with changes in the pancreas (islet cell vacuolation), eye
													(cataracts, lens degeneration), kidney (tubule vacuolation, chronic progressive
													nephropathy) and adipose tissue (atrophy) were identified in a 27 week
													repeat-dose toxicology study in rats that were immature at the beginning of the
													studies and were most prevalent in males at oral palbociclib doses ≥30 mg/kg/day
													(approximately 11 times the adult human exposure [AUC] at the recommended dose).
													Some of these findings (glycosuria/hyperglycemia, pancreatic islet cell
													vacuolation, and kidney tubule vacuolation) were present with lower incidence
													and severity in a 15 week repeat-dose toxicology study in immature rats. Altered
													glucose metabolism or associated changes in the pancreas, eye, kidney and
													adipose tissue were not identified in a 27-week repeat-dose toxicology study in
													rats that were mature at the beginning of the study and in dogs in repeat-dose
													toxicology studies up to 39 weeks duration.</p>
												<p>Toxicities in teeth independent of altered glucose metabolism were observed in
													rats. Administration of 100 mg/kg palbociclib for 27 weeks (approximately 15
													times the adult human exposure [AUC] at the recommended dose) resulted in
													abnormalities in growing incisor teeth (discolored, ameloblast
													degeneration/necrosis, mononuclear cell infiltrate). Other toxicities of
													potential concern to pediatric patients have not been evaluated in juvenile
													animals.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="8.5 Geriatric Use"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="34082-8"/>
											<display value="FDA package insert Geriatric use section"/>
										</coding>
										<text value="GERIATRIC USE SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Of 444 patients who received IBRANCE in PALOMA-2, 181 patients (41%) were ≥65
													years of age and 48 patients (11%) were ≥75 years of age. Of 347 patients who
													received IBRANCE in PALOMA-3, 86 patients (25%) were ≥65 years of age and 27
													patients (8%) were ≥75 years of age. No overall differences in safety or
													effectiveness of IBRANCE were observed between these patients and younger
													patients.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="8.6 Hepatic Impairment"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>No dose adjustment is required in patients with mild or moderate hepatic
													impairment (Child-Pugh classes A and B). For patients with severe hepatic
													impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg once
													daily for 21 consecutive days followed by 7 days off treatment to comprise a
													complete cycle of 28 days <em>[see <a href="S2.2">Dosage and
															Administration (2.2)</a>]</em>. Based on a pharmacokinetic trial in
													subjects with varying degrees of hepatic function, the palbociclib unbound
													exposure (unbound AUC<sub>INF</sub>) decreased by 17% in subjects with mild
													hepatic impairment (Child-Pugh class A), and increased by 34% and 77% in
													subjects with moderate (Child-Pugh class B) and severe (Child-Pugh class C)
													hepatic impairment, respectively, relative to subjects with normal hepatic
													function. Peak palbociclib unbound exposure (unbound C<sub>max</sub>) increased
													by 7%, 38% and 72% for mild, moderate and severe hepatic impairment,
													respectively, relative to subjects with normal hepatic function <em>[see <a href="S12.3">Clinical Pharmacology (12.3)</a>]</em>. </p>
												<p>Review the Full Prescribing Information for the aromatase inhibitor or
													fulvestrant for dose modifications related to hepatic impairment.</p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="8.7 Renal Impairment"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>No dose adjustment is required in patients with mild, moderate, or severe renal
													impairment (CrCl &gt;15 mL/min). Based on a pharmacokinetic trial in subjects
													with varying degrees of renal function, the total palbociclib exposure
													(AUC<sub>INF</sub>) increased by 39%, 42%, and 31% with mild (60 mL/min ≤ CrCl
													&lt;90 mL/min), moderate (30 mL/min ≤ CrCl &lt;60 mL/min), and severe (CrCl
													&lt;30 mL/min) renal impairment, respectively, relative to subjects with normal
													renal function. Peak palbociclib exposure (C<sub>max</sub>) increased by 17%,
													12%, and 15% for mild, moderate, and severe renal impairment, respectively,
													relative to subjects with normal renal function. The pharmacokinetics of
													palbociclib have not been studied in patients requiring hemodialysis <em>[see <a href="S12.3">Clinical Pharmacology (12.3)</a>]</em>.</p>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="10 OVERDOSAGE"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34088-5"/>
										<display value="FDA package insert Overdosage section"/>
									</coding>
									<text value="OVERDOSAGE SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>There is no known antidote for IBRANCE. The treatment of overdose of IBRANCE should
												consist of general supportive measures.</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="11 DESCRIPTION"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34089-3"/>
										<display value="FDA package insert Description section"/>
									</coding>
									<text value="DESCRIPTION SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>IBRANCE capsules for oral administration contain 125 mg, 100 mg, or 75 mg of
												palbociclib, a kinase inhibitor. The molecular formula for palbociclib is
												C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub>. The molecular weight is
												447.54 daltons. The chemical name is
												6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-<em>d</em>]pyrimidin-7(8<em>H</em>)-one,
												and its structural formula is:</p>
											<img src="#ibrance-01" alt="Chemical Structure"/>
											<p>Palbociclib is a yellow to orange powder with pKa of 7.4 (the secondary piperazine
												nitrogen) and 3.9 (the pyridine nitrogen). At or below pH 4, palbociclib behaves as
												a high-solubility compound. Above pH 4, the solubility of the drug substance reduces
												significantly.</p>
											<p>
												<em>Inactive ingredients:</em> Microcrystalline cellulose, lactose monohydrate,
												sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard
												gelatin capsule shells. The light orange, light orange/caramel, and caramel opaque
												capsule shells contain gelatin, red iron oxide, yellow iron oxide, and titanium
												dioxide; the printing ink contains shellac, titanium dioxide, ammonium hydroxide,
												propylene glycol, and simethicone.</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="12 CLINICAL PHARMACOLOGY"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34090-1"/>
										<display value="FDA package insert Clinical pharmacology section"/>
									</coding>
									<text value="CLINICAL PHARMACOLOGY SECTION"/>
								</code>
								<section>
									<title value="12.1 Mechanism of Action"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="43679-0"/>
											<display value="FDA package insert Mechanism of action section"/>
										</coding>
										<text value="MECHANISM OF ACTION SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1
													and CDK4/6 are downstream of signaling pathways which lead to cellular
													proliferation. In vitro, palbociclib reduced cellular proliferation of estrogen
													receptor (ER)-positive breast cancer cell lines by blocking progression of the
													cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell
													lines with the combination of palbociclib and antiestrogens leads to decreased
													retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression
													and signaling, and increased growth arrest compared to treatment with each drug
													alone. In vitro treatment of ER-positive breast cancer cell lines with the
													combination of palbociclib and antiestrogens led to increased cell senescence
													compared to each drug alone, which was sustained for up to 6 days following
													palbociclib removal and was greater if antiestrogen treatment was continued. In
													vivo studies using a patient-derived ER-positive breast cancer xenograft model
													demonstrated that the combination of palbociclib and letrozole increased the
													inhibition of Rb phosphorylation, downstream signaling, and tumor growth
													compared to each drug alone.</p>
												<p>Human bone marrow mononuclear cells treated with palbociclib in the presence or
													absence of an anti-estrogen in vitro did not become senescent and resumed
													proliferation following palbociclib withdrawal. </p>
											</div>
										</div>
									</text>
								</section>
								<section>
									<title value="12.2 Pharmacodynamics"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="43681-6"/>
											<display value="FDA package insert Pharmacodynamics section"/>
										</coding>
										<text value="PHARMACODYNAMICS SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>
													<strong>Cardiac Electrophysiology</strong>
												</p>
												<p>The effect of palbociclib on the QT interval corrected for heart rate (QTc)
														was evaluated using time-matched electrocardiograms (ECGs) evaluating the
														change from baseline and corresponding pharmacokinetic data in 77 patients
														with breast cancer. Palbociclib had no large effect on QTc (i.e., &gt;20 ms)
														at 125 mg once daily for 21 consecutive days followed by 7 days off
														treatment to comprise a complete cycle of 28 days.</p>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="12.3 Pharmacokinetics"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="43682-4"/>
										<display value="FDA package insert Pharmacokinetics section"/>
									</coding>
									<text value="PHARMACOKINETICS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>The pharmacokinetics (PK) of palbociclib were characterized in patients with
													solid tumors including advanced breast cancer and in healthy subjects.</p>
											<p>
												<strong>Absorption</strong>
											</p>
											<p>The mean maximum observed concentration (C<sub>max</sub>) of palbociclib is
														generally observed between 6 to 12 hours (time to reach maximum
														concentration, T<sub>max</sub>) following oral administration. The mean
														absolute bioavailability of IBRANCE after an oral 125 mg dose is 46%. In the
														dosing range of 25 mg to 225 mg, the AUC and C<sub>max</sub> increased
														proportionally with dose in general. Steady state was achieved within 8 days
														following repeated once daily dosing. With repeated once daily
														administration, palbociclib accumulated with a median accumulation ratio of
														2.4 (range 1.5 to 4.2).</p>
											<p>
												<span style="text-decoration: underline; ">Food effect</span>:
															Palbociclib absorption and exposure were very low in approximately 13%
															of the population under the fasted condition. Food intake increased the
															palbociclib exposure in this small subset of the population, but did not
															alter palbociclib exposure in the rest of the population to a clinically
															relevant extent. Therefore, food intake reduced the intersubject
															variability of palbociclib exposure, which supports administration of
															IBRANCE with food. Compared to IBRANCE given under overnight fasted
															conditions, the population average area under the concentration-time
															curve from zero to infinity (AUC<sub>INF</sub>) and C<sub>max</sub> of
															palbociclib increased by 21% and 38%, respectively, when given with
															high-fat, high-calorie food (approximately 800 to 1000 calories with
															150, 250, and 500 to 600 calories from protein, carbohydrate, and fat,
															respectively), by 12% and 27%, respectively, when given with low-fat,
															low-calorie food (approximately 400 to 500 calories with 120, 250, and
															28 to 35 calories from protein, carbohydrate, and fat, respectively),
															and by 13% and 24%, respectively, when moderate-fat, standard calorie
															food (approximately 500 to 700 calories with 75 to 105, 250 to 350 and
															175 to 245 calories from protein, carbohydrate, and fat, respectively)
															was given 1 hour before and 2 hours after IBRANCE dosing.</p>
											<p>
												<strong>Distribution</strong>
											</p>
											<p>Binding of palbociclib to human plasma proteins in vitro was approximately
														85%, with no concentration dependence over the concentration range of 500
														ng/mL to 5000 ng/mL. The mean fraction unbound (f<sub>u</sub>) of
														palbociclib in human plasma in vivo increased incrementally with worsening
														hepatic function. There was no obvious trend in the mean palbociclib
														f<sub>u</sub> in human plasma in vivo with worsening renal function. The
														geometric mean apparent volume of distribution (V<sub>z</sub>/F) was 2583 L
														with a coefficient of variation (CV) of 26%.</p>
											<p>
												<strong>Metabolism</strong>
											</p>
											<p>In vitro and in vivo studies indicated that palbociclib undergoes hepatic
														metabolism in humans. Following oral administration of a single 125 mg dose
														of [<sup>14</sup>C]palbociclib to humans, the primary metabolic pathways for
														palbociclib involved oxidation and sulfonation, with acylation and
														glucuronidation contributing as minor pathways. Palbociclib was the major
														circulating drug-derived entity in plasma (23%). The major circulating
														metabolite was a glucuronide conjugate of palbociclib, although it only
														represented 1.5% of the administered dose in the excreta. Palbociclib was
														extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of
														radioactivity in feces and urine, respectively. In feces, the sulfamic acid
														conjugate of palbociclib was the major drug-related component, accounting
														for 26% of the administered dose. In vitro studies with human hepatocytes,
														liver cytosolic and S9 fractions, and recombinant SULT enzymes indicated
														that CYP3A and SULT2A1 are mainly involved in the metabolism of palbociclib.
													</p>
											<p>
												<strong>Elimination</strong>
											</p>
											<p>The geometric mean apparent oral clearance (CL/F) of palbociclib was 63.1
														L/hr (29% CV), and the mean (± standard deviation) plasma elimination
														half-life was 29 (±5) hours in patients with advanced breast cancer. In 6
														healthy male subjects given a single oral dose of
														[<sup>14</sup>C]palbociclib, a median of 91.6% of the total administered
														radioactive dose was recovered in 15 days; feces (74.1% of dose) was the
														major route of excretion, with 17.5% of the dose recovered in urine. The
														majority of the material was excreted as metabolites.</p>
											<p>
												<strong>Age, Gender, and Body Weight</strong>
											</p>
											<p>Based on a population pharmacokinetic analysis in 183 patients with cancer
														(50 male and 133 female patients, age range from 22 to 89 years, and body
														weight range from 37.9 to 123 kg), gender had no effect on the exposure of
														palbociclib, and age and body weight had no clinically important effect on
														the exposure of palbociclib.</p>
											<p>
												<strong>Pediatric Population</strong>
											</p>
											<p>Pharmacokinetics of IBRANCE have not been evaluated in patients &lt;18 years
														of age.</p>
											<p>
												<strong>Hepatic Impairment</strong>
											</p>
											<p>Data from a pharmacokinetic trial in subjects with varying degrees of hepatic
														impairment indicate that palbociclib unbound AUC<sub>INF</sub> decreased 17%
														in subjects with mild hepatic impairment (Child-Pugh class A), and increased
														by 34% and 77% in subjects with moderate (Child-Pugh class B) and severe
														(Child-Pugh class C) hepatic impairment, respectively, relative to subjects
														with normal hepatic function. Palbociclib unbound C<sub>max</sub> increased
														by 7%, 38% and 72% for mild, moderate and severe hepatic impairment,
														respectively, relative to subjects with normal hepatic function. In
														addition, based on a population pharmacokinetic analysis that included 183
														patients, where 40 patients had mild hepatic impairment based on National
														Cancer Institute (NCI) classification (total bilirubin ≤ ULN and AST &gt;
														ULN, or total bilirubin &gt;1.0 to 1.5 × ULN and any AST), mild hepatic
														impairment had no effect on the exposure of palbociclib, further supporting
														the findings from the dedicated hepatic impairment study.</p>
											<p>
												<strong>Renal Impairment</strong>
											</p>
											<p>Data from a pharmacokinetic trial in subjects with varying degrees of renal
														impairment indicate that palbociclib AUC<sub>INF</sub> increased by 39%,
														42%, and 31% with mild (60 mL/min ≤ CrCl &lt; 90 mL/min), moderate (30
														mL/min ≤ CrCl &lt;60 mL/min), and severe (CrCl &lt;30 mL/min) renal
														impairment, respectively, relative to subjects with normal renal function.
														Peak palbociclib exposure (C<sub>max</sub>) increased by 17%, 12%, and 15%
														for mild, moderate, and severe renal impairment, respectively, relative to
														subjects with normal renal function. In addition, based on a population
														pharmacokinetic analysis that included 183 patients where 73 patients had
														mild renal impairment and 29 patients had moderate renal impairment, mild
														and moderate renal impairment had no effect on the exposure of palbociclib.
														The pharmacokinetics of palbociclib have not been studied in patients
														requiring hemodialysis.</p>
											<p>
												<strong>Drug Interactions</strong>
											</p>
											<p>In vitro data indicate that CYP3A and SULT enzyme SULT2A1 are mainly involved
														in the metabolism of palbociclib. Palbociclib is a weak time-dependent
														inhibitor of CYP3A following daily 125 mg dosing to steady state in humans.
														In vitro, palbociclib is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9,
														2C19, and 2D6, and is not an inducer of CYP1A2, 2B6, 2C8, and 3A4 at
														clinically relevant concentrations.</p>
											<p>
												<em>CYP3A Inhibitors:</em> Data from a drug interaction trial in healthy
															subjects (N=12) indicate that coadministration of multiple 200 mg daily
															doses of itraconazole with a single 125 mg IBRANCE dose increased
															palbociclib AUC<sub>INF</sub> and the C<sub>max</sub> by approximately
															87% and 34%, respectively, relative to a single 125 mg IBRANCE dose
															given alone <em>[see <a href="S7.1">Drug Interactions (7.1</a>)]</em>.
														</p>
											<p>
												<em>CYP3A Inducers:</em> Data from a drug interaction trial in healthy
															subjects (N=15) indicate that coadministration of multiple 600 mg daily
															doses of rifampin, a strong CYP3A inducer, with a single 125 mg IBRANCE
															dose decreased palbociclib AUC<sub>INF</sub> and C<sub>max</sub> by 85%
															and 70%, respectively, relative to a single 125 mg IBRANCE dose given
															alone. Data from a drug interaction trial in healthy subjects (N=14)
															indicate that coadministration of multiple 400 mg daily doses of
															modafinil, a moderate CYP3A inducer, with a single 125 mg IBRANCE dose
															decreased palbociclib AUC<sub>INF</sub> and C<sub>max</sub> by 32% and
															11%, respectively, relative to a single 125 mg IBRANCE dose given alone
															<em>[see <a href="S7.2">Drug Interactions (7.2)</a>]</em>.
														</p>
											<p>
												<em>CYP3A Substrates:</em> Palbociclib is a weak time-dependent inhibitor
															of CYP3A following daily 125 mg dosing to steady state in humans. In a
															drug interaction trial in healthy subjects (N=26), coadministration of
															midazolam with multiple doses of IBRANCE increased the midazolam
															AUC<sub>INF</sub> and the C<sub>max</sub> values by 61% and 37%,
															respectively, as compared to administration of midazolam alone <em>[see
																<a href="S7.3">Drug Interactions (7.3)</a>]</em>.</p>
											<p>
												<em>Gastric pH Elevating Medications:</em> In a drug interaction trial in
															healthy subjects, coadministration of a single 125 mg dose of IBRANCE
															with multiple doses of the proton pump inhibitor (PPI) rabeprazole under
															fed conditions decreased palbociclib C<sub>max</sub> by 41%, but had
															limited impact on AUC<sub>INF</sub> (13% decrease), when compared to a
															single dose of IBRANCE administered alone. Given the reduced effect on
															gastric pH of H2-receptor antagonists and local antacids compared to
															PPIs, the effect of these classes of acid-reducing agents on palbociclib
															exposure under fed conditions is expected to be minimal. Under fed
															conditions there is no clinically relevant effect of PPIs, H2-receptor
															antagonists, or local antacids on palbociclib exposure. In another
															healthy subject study, coadministration of a single dose of IBRANCE with
															multiple doses of the PPI rabeprazole under fasted conditions decreased
															palbociclib AUC<sub>INF</sub> and C<sub>max</sub> by 62% and 80%,
															respectively, when compared to a single dose of IBRANCE administered
															alone.</p>
											<p>
												<em>Letrozole:</em> Data from a clinical trial in patients with breast
															cancer showed that there was no drug interaction between palbociclib and
															letrozole when the 2 drugs were coadministered.</p>
											<p>
												<em>Fulvestrant:</em> Data from a clinical trial in patients with breast
															cancer showed that there was no clinically relevant drug interaction
															between palbociclib and fulvestrant when the 2 drugs were
															coadministered.</p>
											<p>
												<em>Goserelin:</em> Data from a clinical trial in patients with breast
															cancer showed that there was no clinically relevant drug interaction
															between palbociclib and goserelin when the 2 drugs were coadministered.
														</p>
											<p>
												<em>Anastrozole or Exemestane:</em> No clinical data are available to
															evaluate drug interactions between anastrozole or exemestane and
															palbociclib. A clinically significant drug interaction between
															anastrozole or exemestane and palbociclib is not expected based on
															analyses of the effects of anastrozole, exemestane and palbociclib on or
															by metabolic pathways or transporter systems. </p>
											<p>
												<em>Effect of Palbociclib on Transporters:</em> In vitro evaluations
															indicated that palbociclib has a low potential to inhibit the activities
															of drug transporters organic anion transporter (OAT)1, OAT3, organic
															cation transporter (OCT)2, and organic anion transporting polypeptide
															(OATP)1B1, OATP1B3 at clinically relevant concentrations. In vitro,
															palbociclib has the potential to inhibit OCT1 at clinically relevant
															concentrations, as well as the potential to inhibit P-glycoprotein
															(P-gp) or breast cancer resistance protein (BCRP) in the
															gastrointestinal tract at the proposed dose.</p>
											<p>
												<em>Effect of Transporters on Palbociclib:</em> Based on in vitro data,
															P-gp and BCRP mediated transport are unlikely to affect the extent of
															oral absorption of palbociclib at therapeutic doses.</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="13 NONCLINICAL TOXICOLOGY"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="43680-8"/>
										<display value="FDA package insert Nonclinical toxicology section"/>
									</coding>
									<text value="NONCLINICAL TOXICOLOGY SECTION"/>
								</code>
								<section>
									<title value="13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="34083-6"/>
											<display value="FDA package insert Carcinogenesis and mutagenesis and impairment of fertility section"/>
										</coding>
										<text value="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>Palbociclib was assessed for carcinogenicity in a 6-month transgenic mouse study
													and in a 2-year rat study. Oral administration of palbociclib for 2 years
													resulted in an increased incidence of microglial cell tumors in the central
													nervous system of male rats at a dose of 30 mg/kg/day (approximately 8 times the
													human clinical exposure based on AUC). There were no neoplastic findings in
													female rats at doses up to 200 mg/kg/day (approximately 5 times the human
													clinical exposure based on AUC). Oral administration of palbociclib to male and
													female rasH2 transgenic mice for 6 months did not result in increased incidence
													of neoplasms at doses up to 60 mg/kg/day. </p>
												<p>Palbociclib was aneugenic in Chinese Hamster Ovary cells in vitro and in the bone
													marrow of male rats at doses ≥100 mg/kg/day for 3 weeks. Palbociclib was not
													mutagenic in an in vitro bacterial reverse mutation (Ames) assay and was not
													clastogenic in the in vitro human lymphocyte chromosome aberration assay.</p>
												<p>In a fertility study in female rats, palbociclib did not affect mating or
													fertility at any dose up to 300 mg/kg/day (approximately 4 times human clinical
													exposure based on AUC) and no adverse effects were observed in the female
													reproductive tissues in repeat-dose toxicity studies up to 300 mg/kg/day in the
													rat and 3 mg/kg/day in the dog (approximately 6 times and similar to human
													exposure [AUC], at the recommended dose, respectively).</p>
												<p>The adverse effects of palbociclib on male reproductive function and fertility
													were observed in the repeat-dose toxicology studies in rats and dogs and a male
													fertility study in rats. In repeat-dose toxicology studies, palbociclib-related
													findings in the testis, epididymis, prostate, and seminal vesicle at ≥30
													mg/kg/day in rats and ≥0.2 mg/kg/day in dogs included decreased organ weight,
													atrophy or degeneration, hypospermia, intratubular cellular debris, and
													decreased secretion. Partial reversibility of male reproductive organ effects
													was observed in the rat and dog following a 4- and 12-week non-dosing period,
													respectively. These doses in rats and dogs resulted in approximately ≥10 and 0.1
													times, respectively, the exposure [AUC] in humans at the recommended dose. In
													the fertility and early embryonic development study in male rats, palbociclib
													caused no effects on mating but resulted in a slight decrease in fertility in
													association with lower sperm motility and density at 100 mg/kg/day with
													projected exposure levels [AUC] of 20 times the exposure in humans at the
													recommended dose.</p>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="14 CLINICAL STUDIES"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34092-7"/>
										<display value="FDA package insert Clinical studies section"/>
									</coding>
									<text value="CLINICAL STUDIES SECTION"/>
								</code>
								<section>
									<title value="PALOMA-2: IBRANCE plus Letrozole"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="additional"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<div style="narrative">
												<p>
													<strong>Patients with ER-positive, HER2-negative advanced or metastatic
															breast cancer for initial endocrine based therapy</strong>
												</p>
												<p>PALOMA-2 was an international, randomized, double-blind, parallel-group,
														multicenter study of IBRANCE plus letrozole versus placebo plus letrozole
														conducted in postmenopausal women with ER-positive, HER2-negative advanced
														breast cancer who had not received previous systemic treatment for their
														advanced disease. A total of 666 patients were randomized 2:1 to IBRANCE
														plus letrozole or placebo plus letrozole. Randomization was stratified by
														disease site (visceral versus non-visceral), disease-free interval (de novo
														metastatic versus ≤12 months from the end of adjuvant treatment to disease
														recurrence versus &gt;12 months from the end of adjuvant treatment to
														disease recurrence), and nature of prior (neo)adjuvant anticancer therapies
														(prior hormonal therapies versus no prior hormonal therapy). IBRANCE was
														given orally at a dose of 125 mg daily for 21 consecutive days followed by 7
														days off treatment. Patients received study treatment until objective
														disease progression, symptomatic deterioration, unacceptable toxicity,
														death, or withdrawal of consent, whichever occurred first. The major
														efficacy outcome of the study was investigator-assessed progression-free
														survival (PFS) evaluated according to Response Evaluation Criteria in Solid
														Tumors Version 1.1 (RECIST). Additional efficacy outcome measures were
														confirmed overall response rate (ORR) as assessed by the investigator
														according to RECIST Version 1.1 and overall survival (OS).</p>
												<p>Patients enrolled in this study had a median age of 62 years (range 28 to
														89). The majority of patients were White (78%), and most patients had an
														Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
														(98%). Forty-eight percent of patients had received chemotherapy and 56% had
														received antihormonal therapy in the neoadjuvant or adjuvant setting prior
														to their diagnosis of advanced breast cancer. Thirty-seven percent of
														patients had no prior systemic therapy in the neoadjuvant or adjuvant
														setting. The majority of patients (97%) had metastatic disease. Twenty-three
														percent of patients had bone only disease, and 49% of patients had visceral
														disease.</p>
												<p>Major efficacy results from PALOMA-2 are summarized in Table 8 and Figure 1.
														Consistent results were observed across patient subgroups of disease-free
														interval (DFI), disease site, and prior therapy. The treatment effect of the
														combination on PFS was also supported by an independent review of
														radiographs. Based on the prespecified final OS analysis conducted after 435
														events, OS was not statistically significant.</p>
												<table width="80%">
													<caption>Table 8. Efficacy Results – PALOMA-2</caption>
													<colgroup span="3">
														<col width="40%"/>
														<col width="26%"/>
														<col width="26%"/>
													</colgroup>
													<thead>
														<tr>
															<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
															<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																<strong>IBRANCE plus Letrozole</strong>
															</td>
															<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
																<strong>Placebo plus Letrozole</strong>
															</td>
														</tr>
													</thead>
													<tfoot>
														<tr>
															<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="3">CI=confidence interval; ITT=Intent-to-Treat;
																	N=number of patients; NE=not estimable; OS=overall survival;
																	PFS=progression-free survival.</td>
														</tr>
													</tfoot>
													<tbody>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
																<p>
																	<strong>Progression-free survival for ITT (investigator
																			assessment)</strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>N=444</strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>N=222</strong>
																</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>  Number of PFS events (%)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">194 (43.7)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">137 (61.7)</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>  Median progression-free survival (months, 95% CI)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">24.8 (22.1, NE)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">14.5 (12.9, 17.1)</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>  Hazard ratio (95% CI) and p-value</p>
															</td>
															<td colspan="2" style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">0.576 (0.463, 0.718),
																		p&lt;0.0001
			</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>
																	<strong>Objective Response for patients with measurable
																			disease (investigator assessment)</strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>N=338</strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>N=171</strong>
																</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>  Objective response rate (%, 95%
																		CI)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">55.3 (49.9, 60.7)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">44.4 (36.9, 52.2)</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>
																	<strong>Overall survival for ITT </strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>N=444</strong>
																</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>N=222</strong>
																</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>  Number of OS events (%) </p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">287 (64.6)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">148 (66.7) </p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
																<p>  Median OS (months, 95% CI) </p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">53.8 (49.8, 59.2)</p>
															</td>
															<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">49.8 (42.3, 56.4)</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
																<p>  Hazard ratio (95% CI) and p‑value </p>
															</td>
															<td colspan="2" style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
																<p style="text-align: center; ">0.921 (0.755, 1.124),
																		p=0.2087
			</p>
															</td>
														</tr>
													</tbody>
												</table>
												<p>
			Cox
														proportional hazards model stratified by disease site (visceral vs.
														non-visceral) per randomization.</p>
												<p>
			Stratified log-rank test
														one-sided p-value.</p>
												<p>
			Response
														is based on confirmed responses.</p>
												<table width="100%">
													<colgroup span="1">
														<col width="100%"/>
													</colgroup>
													<tbody>
														<tr>
															<td style="text-align: center; text-align: center; " align="center">
																<p style="text-align: center; ">
																	<strong>Figure 1. Kaplan-Meier
																			Plot of Progression-Free Survival – PALOMA-2
																			(Investigator Assessment, Intent-to-Treat
																			Population)</strong>
																	<br/>
																</p>
															</td>
														</tr>
														<tr>
															<td style="text-align: center; text-align: center; " align="center">
																<p style="text-align: center; ">LET=letrozole; PAL=palbociclib;
																		PBO=placebo.</p>
															</td>
														</tr>
													</tbody>
												</table>
											</div>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="PALOMA-3: IBRANCE plus Fulvestrant"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="FDA package insert Structured patient labelling unclassified section"/>
									</coding>
									<text value="SPL UNCLASSIFIED SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>
												<strong>Patients with HR-positive, HER2-negative advanced or metastatic
															breast cancer who have had disease progression on or after prior
															adjuvant or metastatic endocrine therapy</strong>
											</p>
											<p>PALOMA-3 was an international, randomized, double-blind, parallel group,
														multicenter study of IBRANCE plus fulvestrant versus placebo plus
														fulvestrant conducted in women with HR-positive, HER2-negative advanced
														breast cancer, regardless of their menopausal status, whose disease
														progressed on or after prior endocrine therapy. A total of 521
														pre/postmenopausal women were randomized 2:1 to IBRANCE plus fulvestrant or
														placebo plus fulvestrant and stratified by documented sensitivity to prior
														hormonal therapy, menopausal status at study entry (pre/peri versus
														postmenopausal), and presence of visceral metastases. IBRANCE was given
														orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days
														off treatment. Pre/perimenopausal women were enrolled in the study and
														received the LHRH agonist goserelin for at least 4 weeks prior to and for
														the duration of PALOMA-3. Patients continued to receive assigned treatment
														until objective disease progression, symptomatic deterioration, unacceptable
														toxicity, death, or withdrawal of consent, whichever occurred first. The
														major efficacy outcome of the study was investigator-assessed PFS evaluated
														according to RECIST 1.1.</p>
											<p>Patients enrolled in this study had a median age of 57 years (range 29 to
														88). The majority of patients on study were White (74%), all patients had an
														ECOG PS of 0 or 1, and 80% were postmenopausal. All patients had received
														prior systemic therapy, and 75% of patients had received a previous
														chemotherapy regimen. Twenty-five percent of patients had received no prior
														therapy in the metastatic disease setting, 60% had visceral metastases, and
														23% had bone only disease.</p>
											<p>The results from the investigator-assessed PFS and final OS from PALOMA-3 are
														summarized in Table 9. The relevant Kaplan-Meier plots are shown in Figures
														2 and 3, respectively. Consistent PFS results were observed across patient
														subgroups of disease site, sensitivity to prior hormonal therapy, and
														menopausal status. After a median follow-up time of 45 months, the final OS
														results were not statistically significant.</p>
											<table width="80%">
												<caption>Table 9. Efficacy Results – PALOMA-3</caption>
												<colgroup span="3">
													<col width="40%"/>
													<col width="26%"/>
													<col width="26%"/>
												</colgroup>
												<thead>
													<tr>
														<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>IBRANCE plus Fulvestrant</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Placebo plus Fulvestrant</strong>
														</td>
													</tr>
												</thead>
												<tfoot>
													<tr>
														<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="3">CI=confidence interval; ITT=Intent-to-Treat;
																	N=number of patients; OS=overall survival; PFS=progression-free
																	survival.</td>
													</tr>
												</tfoot>
												<tbody>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>
																<strong>Progression-free survival for
																			ITT</strong>
																<br/>
																<strong>(investigator
																			assessment)</strong>
															</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>N=347</strong>
															</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>N=174</strong>
															</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Number of PFS events (%)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">145 (41.8)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">114 (65.5)</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Median PFS (months, 95% CI)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">9.5 (9.2, 11.0)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">4.6 (3.5, 5.6)</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Hazard ratio (95% CI) and p-value</p>
														</td>
														<td colspan="2" style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0.461 (0.360, 0.591),
																		p&lt;0.0001</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>
																<strong>Objective Response for patients with measurable
																			disease</strong>
																<br/>
																<strong>(investigator
																			assessment)</strong>
															</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>N=267</strong>
															</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>N=138</strong>
															</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Objective response rate (%, 95%
																		CI)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">24.6 (19.6, 30.2)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">10.9 (6.2, 17.3)</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>
																<strong>Overall survival for ITT </strong>
															</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>N=347</strong>
															</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>N=174</strong>
															</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Number of OS events (%)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">201 (57.9)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">109 (62.6)</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Median OS (months, 95% CI)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">34.9 (28.8, 40.0)</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">28.0 (23.6, 34.6)</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
															<p>  Hazard ratio (95% CI) and p-value</p>
														</td>
														<td colspan="2" style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0.814 (0.644, 1.029), p=0.0857</p>
														</td>
													</tr>
												</tbody>
											</table>
											<p>
			Responses are based on
														confirmed responses.</p>
											<p>
			Not
														statistically significant at the pre-specified 2-sided alpha level of 0.047.
													</p>
											<p>
			2-sided
														p-value from the log-rank test stratified by the presence of visceral
														metastases and sensitivity to prior endocrine therapy per randomization.</p>
											<table width="100%">
												<colgroup span="1">
													<col width="100%"/>
												</colgroup>
												<tbody>
													<tr>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>Figure 2. Kaplan-Meier
																			Plot of Progression-Free Survival – PALOMA-3
																			(Investigator Assessment, Intent-to-Treat Population)
																		</strong>
															</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; text-align: left; ">
															<p/>
														</td>
													</tr>
													<tr>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">FUL=fulvestrant;
																		PAL=palbociclib; PBO=placebo.</p>
														</td>
													</tr>
												</tbody>
											</table>
											<table width="100%">
												<colgroup span="1">
													<col width="100%"/>
												</colgroup>
												<tbody>
													<tr>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">
																<strong>Figure 3. Kaplan-Meier
																			Plot of Overall Survival (Intent-to-Treat Population) –
																			PALOMA-3</strong>
															</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; text-align: left; ">
															<p/>
														</td>
													</tr>
													<tr>
														<td style="text-align: center; text-align: center; " align="center">
															<p style="text-align: center; ">FUL=fulvestrant;
																		PAL=palbociclib; PBO=placebo.</p>
														</td>
													</tr>
												</tbody>
											</table>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="16 HOW SUPPLIED/STORAGE AND HANDLING"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34069-5"/>
										<display value="FDA package insert How supplied section"/>
									</coding>
									<text value="HOW SUPPLIED SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>IBRANCE is supplied in the following strengths and package configurations:</p>
											<table width="75%">
												<colgroup span="4">
													<col width="19%"/>
													<col width="18%"/>
													<col width="18%"/>
													<col width="32%"/>
												</colgroup>
												<thead>
													<tr>
														<td colspan="4" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>IBRANCE Capsules</strong>
														</td>
													</tr>
													<tr>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Package Configuration</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Capsule Strength (mg)</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>NDC</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Capsule Description</strong>
														</td>
													</tr>
												</thead>
												<tbody>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>Bottles of 21 capsules</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">125</p>
														</td>
														<td style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>NDC 0069-0189-21</p>
														</td>
														<td style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>opaque, hard gelatin capsules, size 0, with caramel cap and body,
																printed with white ink "Pfizer" on the cap, "PBC 125" on the body
															</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Bottles of 21 capsules</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">100</p>
														</td>
														<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
															<p>NDC 0069-0188-21</p>
														</td>
														<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
															<p>opaque, hard gelatin capsules, size 1, with caramel cap and light
																orange body, printed with white ink "Pfizer" on the cap, "PBC 100"
																on the body</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
															<p>Bottles of 21 capsules</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">75</p>
														</td>
														<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
															<p>NDC 0069-0187-21</p>
														</td>
														<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
															<p>opaque, hard gelatin capsules, size 2, with light orange cap and
																body, printed with white ink "Pfizer" on the cap, "PBC 75" on the
																body</p>
														</td>
													</tr>
												</tbody>
											</table>
											<p>Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to
													30 °C (59 °F to 86 °F) <em>[see USP Controlled Room Temperature]</em>.</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="17 PATIENT COUNSELING INFORMATION"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="34076-0"/>
										<display value="FDA package insert Information for patients section"/>
									</coding>
									<text value="INFORMATION FOR PATIENTS SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p style="text-decoration: underline; ">Myelosuppression/Infection</p>
											<ul>
												<li>Advise patients to immediately report any signs or symptoms of
														myelosuppression or infection, such as fever, chills, dizziness, shortness
														of breath, weakness, or any increased tendency to bleed and/or to bruise
														<em>[see <a href="S5.1">Warnings and Precautions (5.1)</a>]</em>.
													</li>
											</ul>
											<p style="text-decoration: underline; ">Interstitial Lung Disease/Pneumonitis</p>
											<ul>
												<li>Advise patients to immediately report new or worsening respiratory symptoms
														<em>[see <a href="S5.2">Warnings and Precautions (5.2)</a>]</em>.
													</li>
											</ul>
											<p style="text-decoration: underline; ">Drug Interactions</p>
											<ul>
												<li>Grapefruit may interact with IBRANCE. Patients should not consume grapefruit
														products while on treatment with IBRANCE.</li>
												<li>Inform patients to avoid strong CYP3A inhibitors and strong CYP3A inducers.
													</li>
												<li>Advise patients to inform their healthcare providers of all concomitant
														medications, including prescription medicines, over-the-counter drugs,
														vitamins, and herbal products <em>[see <a href="S7.3">Drug Interactions
																(7)</a>]</em>.</li>
											</ul>
											<p style="text-decoration: underline; ">Dosing and Administration</p>
											<ul>
												<li>Advise patients to take IBRANCE with food.</li>
												<li>If the patient vomits or misses a dose, an additional dose should not be
														taken. The next prescribed dose should be taken at the usual time. IBRANCE
														capsules should be swallowed whole (do not chew, crush, or open them prior
														to swallowing). No capsule should be ingested if it is broken, cracked, or
														otherwise not intact.</li>
												<li>Pre/perimenopausal women treated with IBRANCE should also be treated with
														LHRH agonists <em>[see <a href="S2.1">Dosage and Administration
																(2.1)</a>]</em>.</li>
											</ul>
											<p style="text-decoration: underline; ">Pregnancy, Lactation, and Infertility</p>
											<ul>
												<li>Embryo-Fetal Toxicity<ul>
														<li>Advise females of reproductive potential of the potential risk to a
																fetus and to use effective contraception during treatment with
																IBRANCE therapy and for at least 3 weeks after the last dose. Advise
																females to inform their healthcare provider of a known or suspected
																pregnancy <em>[see <a href="S5.3">Warnings and Precautions
																		(5.3)</a> and <a href="S8.1">Use in Specific
																		Populations (8.1</a> and <a href="S8.3">8.3)</a>]</em>.</li>
														<li>Advise male patients with female partners of reproductive potential
																to use effective contraception during treatment with IBRANCE and for
																at least 3 months after the last dose <em>[see <a href="S8.3">Use in Specific Populations
																		(8.3)</a>].</em>
														</li>
													</ul>
												</li>
												<li>Lactation: Advise women not to breastfeed during treatment with IBRANCE and
														for 3 weeks after the last dose <em>[see <a href="S8.2">Use in
																Specific Populations (8.2)</a>].</em>
												</li>
												<li>Infertility: Inform males of reproductive potential that IBRANCE may cause
														infertility and to consider sperm preservation before taking IBRANCE
														<em>[see <a href="S8.3">Use in Specific Populations (8.3)</a>]</em>.
													</li>
											</ul>
											<p>This product's label may have been updated. For full prescribing information, please
												visit <a href="http://www.Pfizer.com">www.Pfizer.com</a>. For medical information
												about IBRANCE, please visit <a href="http://www.pfizermedinfo.com">www.pfizermedinfo.com</a> or call
												1-800-438-1985.</p>
											<p>LAB-0723-10.0</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="SPL PATIENT PACKAGE INSERT SECTION"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="42230-3"/>
										<display value="FDA package insert Structured product laballing patient package insert section"/>
									</coding>
									<text value="SPL PATIENT PACKAGE INSERT SECTION"/>
								</code>
								<section>
									<!-- id value="NESTED-SECTION-1"/ -->
									<title value="PATIENT INFORMATION"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<b> IBRANCE <sup>®</sup> (EYE-brans) <br/> (palbociclib) </b>
											<br/>
											Tablets
										</div>
									</text>
								</section>
								<section>
									<title value="What is the most important information I should know about IBRANCE?"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>
												<b>IBRANCE may cause serious side effects, including:</b>
											</p>
											<p>
												<b>Low white blood cell counts (neutropenia).</b> Low white
												blood cell counts are very common when taking IBRANCE and may
												cause serious infections that can lead to death. Your healthcare
												provider should check your white blood cell counts before and
												during treatment.
											</p>
											<p>
												If you develop low white blood cell counts during treatment with
												IBRANCE, your healthcare provider may stop your treatment,
												decrease your dose, or may tell you to wait to begin your
												treatment cycle. Tell your healthcare provider right away if you
												have signs and symptoms of low white blood cell counts or
												infections such as fever and chills.
											</p>
											<p>
												<b>Lung problems (pneumonitis).</b> IBRANCE may cause severe or
												life-threatening inflammation of the lungs during treatment that
												can lead to death. Tell your healthcare provider right away if
												you have any new or worsening symptoms, including:
											</p>
											<ul>
												<li>chest pain</li>
												<li>cough with or without mucus</li>
												<li>trouble breathing or shortness of breath</li>
											</ul>
											<p>
												Your healthcare provider may interrupt or stop treatment with
												IBRANCE completely if your symptoms are severe.
											</p>
											<p>
												<b> See <a>"What are the possible side effects of
														IBRANCE?"</a> for more information about side effects. </b>
											</p>
										</div>
									</text>
								</section>
								<section>
									<!-- id value="NESTED-SECTION-3"/ -->
									<title value="What is IBRANCE?"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>
												IBRANCE is a prescription medicine used in adults to treat
												hormone receptor (HR)-positive, human epidermal growth factor
												receptor 2 (HER2)-negative breast cancer that has spread to
												other parts of the body (metastatic) in combination with:
											</p>
											<ul>
												<li>an aromatase inhibitor as the first hormonal based therapy
													in postmenopausal women or in men, or</li>
												<li>fulvestrant in people with disease progression following
													hormonal therapy.</li>
											</ul>
											<p>
												It is not known if IBRANCE is safe and effective in children.
											</p>
										</div>
									</text>
								</section>
								<section>
									<title value="Before taking IBRANCE, tell your healthcare provider about all of your medical conditions, including if you:"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<ul>
												<li>have fever, chills, or any other signs or symptoms of
													infection.</li>
												<li>have liver or kidney problems.</li>
												<li>are pregnant, or plan to become pregnant. IBRANCE can harm
													your unborn baby.</li>
												<li>
													<ul>
														<li>Females who are able to become pregnant should use
															effective birth control during treatment and for at
															least 3 weeks after the last dose of IBRANCE. Your
															healthcare provider may ask you to take a pregnancy
															test before you start treatment with IBRANCE.</li>
														<li>Males with female partners who can become pregnant
															should use effective birth control during treatment
															with IBRANCE for at least 3 months after the last
															dose of IBRANCE.</li>
														<li>Talk to your healthcare provider about birth control
															methods that may be right for you during this time.</li>
														<li>If you become pregnant or think you are pregnant,
															tell your healthcare provider right away.</li>
													</ul>
												</li>
												<li>are breastfeeding or plan to breastfeed. It is not known if
													IBRANCE passes into your breast milk. Do not breastfeed
													during treatment with IBRANCE and for 3 weeks after the last
													dose.</li>
											</ul>
											<p>
												<b>Tell your healthcare provider about all of the medicines you
													take, including</b> prescription and over-the-counter medicines,
												vitamins, and herbal supplements. IBRANCE and other medicines
												may affect each other causing side effects.
											</p>
										</div>
									</text>
								</section>
								<section>
									<title value="How should I take IBRANCE?"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<ul>
												<li>Take IBRANCE exactly as your healthcare provider tells you.</li>
												<li>IBRANCE tablets may be taken with or without food.</li>
												<li>IBRANCE should be taken at about the same time each day.</li>
												<li>Swallow IBRANCE tablets whole. Do not chew, crush or split
													IBRANCE tablets before swallowing them.</li>
												<li>Do not take any IBRANCE tablets that are broken, cracked, or
													that look damaged.</li>
												<li>Avoid grapefruit and grapefruit products during treatment
													with IBRANCE. Grapefruit may increase the amount of IBRANCE
													in your blood.</li>
												<li>Do not change your dose or stop taking IBRANCE unless your
													healthcare provider tells you.</li>
												<li>If you miss a dose of IBRANCE or vomit after taking a dose
													of IBRANCE, do not take another dose on that day. Take your
													next dose at your regular time.</li>
												<li>If you take too much IBRANCE, call your healthcare provider
													right away or go to the nearest hospital emergency room.</li>
											</ul>
										</div>
									</text>
								</section>
								<section>
									<title value="What are the possible side effects of IBRANCE?"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>
												<b> IBRANCE may cause serious side effects. See <a>"What
														is the most important information I should know about
														IBRANCE?"</a>
												</b>
											</p>
											<p>
												<b>The most common side effects of IBRANCE when used with either
													letrozole or fulvestrant include:</b>
											</p>
											<ul>
												<li> Low red blood cell counts and low platelet counts are
													common with IBRANCE. Call your healthcare provider right
													away if you develop any of these symptoms during treatment: <ul>
														<li>dizziness</li>
														<li>shortness of breath</li>
														<li>weakness</li>
														<li>bleeding or bruising more easily</li>
														<li>nosebleeds</li>
													</ul>
												</li>
												<li> infections (see <a>"What is the most important
														information I should know about IBRANCE?</a>") </li>
												<li>tiredness</li>
												<li>nausea</li>
												<li>sore mouth</li>
												<li>abnormalities in liver blood tests</li>
												<li>diarrhea</li>
												<li>hair thinning or hair loss</li>
												<li>vomiting</li>
												<li>rash</li>
												<li>loss of appetite</li>
											</ul>
											<p>
												IBRANCE may cause fertility problems in males. This may affect
												your ability to father a child. Talk to your healthcare provider
												about family planning options before starting IBRANCE if this is
												a concern for you.
											</p>
											<p>
												These are not all of the possible side effects of IBRANCE.
											</p>
											<p>
												Call your doctor for medical advice about side effects. You may
												report side effects to FDA at 1-800-FDA-1088.
											</p>
										</div>
									</text>
								</section>
								<section>
									<title value="How should I store IBRANCE?"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<ul>
												<li>Store IBRANCE at 68 °F to 77 °F (20 °C to 25 °C) in the
													original blister pack.</li>
											</ul>
											<p>
												<b>Keep IBRANCE and all medicines out of the reach of children.</b>
											</p>
										</div>
									</text>
								</section>
								<section>
									<title value="General information about the safe and effective use of IBRANCE"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>
												Medicines are sometimes prescribed for purposes other than those
												listed in a Patient Information leaflet. Do not use IBRANCE for
												a condition for which it was not prescribed. Do not give IBRANCE
												to other people, even if they have the same symptoms you have.
												It may harm them. You can ask your pharmacist or healthcare
												provider for more information about IBRANCE that is written for
												health professionals.
											</p>
										</div>
									</text>
								</section>
								<section>
									<title value="What are the ingredients in IBRANCE?"/>
									<code>
										<coding>
											<system value="http://loinc.org"/>
											<code value="42229-5"/>
											<display value="FDA package insert Structured patient labelling unclassified section"/>
										</coding>
										<text value="SPL UNCLASSIFIED SECTION"/>
									</code>
									<text>
										<status value="generated"/>
										<div xmlns="http://www.w3.org/1999/xhtml">
											<p>
												Active ingredient: palbociclib
											</p>
											<p>
												Inactive ingredients: microcrystalline cellulose, colloidal
												silicon dioxide, crospovidone, magnesium stearate, succinic
												acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and
												FD&amp;C Blue #2/Indigo Carmine Aluminum Lake. In addition, the
												75 mg and 125 mg tablets contain red iron oxide and the 100 mg
												tablets contain yellow iron oxide.
											</p>
											<p>
												LAB-1372-1.0
											</p>
											<p>
												For more information, go to www.IBRANCE.com or call
												1-800-438-1985.
											</p>
										</div>
									</text>
								</section>
							</section>
							<section>
								<title value="PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="51945-4"/>
										<display value="FDA product label Principal display panel of package"/>
									</coding>
									<text value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>NDC 0069-0187-21</p>
											<p>
												<strong>
													<em>Pfizer</em>
												</strong>
											</p>
											<p>
												<strong>Ibrance</strong>
												<sup>®</sup>
												<br/>
												<strong>(palbociclib)</strong>
												<br/>
												<strong>capsules</strong>
											</p>
											<p>
												<strong>75 mg</strong>
											</p>
											<p>21 Capsules</p>
											<p>
												<strong>Rx only</strong>
											</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="51945-4"/>
										<display value="FDA product label Principal display panel of package"/>
									</coding>
									<text value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>NDC 0069-0188-21</p>
											<p>
												<strong>
													<em>Pfizer</em>
												</strong>
											</p>
											<p>
												<strong>Ibrance</strong>
												<sup>®</sup>
												<br/>
												<strong>(palbociclib)</strong>
												<br/>
												<strong>capsules</strong>
											</p>
											<p>
												<strong>100 mg</strong>
											</p>
											<p>21 Capsules</p>
											<p>
												<strong>Rx only</strong>
											</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="PRINCIPAL DISPLAY PANEL - 125 mg Capsule Bottle Label"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="51945-4"/>
										<display value="FDA product label Principal display panel of package"/>
									</coding>
									<text value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
								</code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>NDC 0069-0189-21</p>
											<p>
												<strong>
													<em>Pfizer</em>
												</strong>
											</p>
											<p>
												<strong>Ibrance</strong>
												<sup>®</sup>
												<br/>
												<strong>(palbociclib)</strong>
												<br/>
												<strong>capsules</strong>
											</p>
											<p>
												<strong>125 mg</strong>
											</p>
											<p>21 Capsules</p>
											<p>
												<strong>Rx only</strong>
											</p>
										</div>
									</div>
								</text>
							</section>
							<section>
								<title value="Annotations"/>
								<code>
									<coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="FDA package insert Structured patient labelling unclassified section"/>
									</coding>
									<text value="SPL UNCLASSIFIED SECTION"/>
								</code>
								<text>
									<status value="additional"/>
									<div class="comments" xmlns="http://www.w3.org/1999/xhtml">
									<div class="trackChanges" xmlns="http://www.w3.org/1999/xhtml">
										<div class="Delete" title="del01">
											<span class="Author" title="FDA"/>
											<span class="Date" title="2024-11-25T10:00:00Z"/>
											<p>None</p>
										</div>
										<div class="Delete" title="del02">
											<span class="Author" title="Pfizer"/>
											<span class="Date" title="2025-01-22T10:00:00Z"/>
											<p>None</p>
										</div>
										<div class="Insert" title="ins01">
											<span class="Author" title="Pfizer"/>
											<span class="Date" title="2025-01-28T10:00:00Z"/>
											<p>None</p>
										</div>
										<div class="Insert" title="ins02">
											<span class="Author" title="Pfizer"/>
											<span class="Date" title="2025-01-28T11:00:00Z"/>
											<p>None</p>
										</div>
										<div class="Insert" title="ins03">
											<span class="Author" title="Pfizer"/>
											<span class="Date" title="2025-01-28T16:00:00Z"/>
											<p>None</p>
										</div>
										<div class="Insert" title="ins04">
											<span class="Author" title="Pfizer"/>
											<span class="Date" title="2025-01-29T10:00:00Z"/>
											<p>None</p>
										</div>
									</div>
									</div>
								</text>
							</section>
						</Composition>
					</resource>
				</entry>
				<entry>
					<fullUrl value="http://hl7.org/fhir/Organization/134489525"/>
					<resource>
						<Organization>
							<id value="134489525"/>
							<meta>
								<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
							</meta>
							<text>
								<status value="generated"/>
								<div xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
			Pfizer Laboratories Div Pfizer Inc <br/>
								</div>
							</text>
							<identifier>
								<system value="urn:oid:1.3.6.1.4.1.519.1"/>
								<value value="134489525"/>
							</identifier>
							<type>
								<!-- coding>
			<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes"/>
			<code value="Labeler"/>
			</coding -->
								<text value="Labeler"/>
							</type>
							<name value="Pfizer Laboratories Div Pfizer Inc"/>
						</Organization>
					</resource>
				</entry>
				<entry>
					<fullUrl value="http://hl7.org/fhir/MedicinalProductDefinition/MPDPALBOCICLIB75"/>
					<resource>
						<MedicinalProductDefinition>
							<id value="MPDPALBOCICLIB75"/>
							<meta>
								<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi|1.0.0"/>
							</meta>
							<text>
								<status value="generated"/>
								<div xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
			MPDPALBOCICLIB75 <br/>
								</div>
							</text>
							<identifier>
								<system value="http://hl7.org/fhir/sid/ndc"/>
								<value value="0069-0187"/>
							</identifier>
							<type>
								<coding>
									<system value="http://ncit.nci.nih.gov"/>
									<code value="C121840"/>
									<display value="Approved for Human Use Product"/>
								</coding>
							</type>
							<domain>
								<coding>
									<system value="http://ncit.nci.nih.gov"/>
									<code value="C14225"/>
									<display value="Human"/>
								</coding>
							</domain>
							<version value="1"/>
							<status>
								<coding>
									<system value="http://hl7.org/fhir/publication-status"/>
									<code value="active"/>
									<display value="Active"/>
								</coding>
							</status>
							<statusDate value="2020-03-30"/>
							<route>
								<coding>
									<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
									<code value="C38288"/>
									<display value="ORAL"/>
								</coding>
							</route>
							<marketingStatus>
								<status>
									<!-- coding>
			<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses"/>
			<code value="active"/>
			</coding -->
									<text value="active"/>
								</status>
								<dateRange>
									<start value="2015-02-03"/>
								</dateRange>
							</marketingStatus>
							<name>
								<productName value="IBRANCE® (palbociclib) tablets - 75 mg"/>
								<part>
									<part value="palbociclib"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C71898"/>
										</coding>
										<text value="Proprietary Name"/>
									</type>
								</part>
								<part>
									<part value="palbociclib"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C3273150"/>
										</coding>
										<text value="NONPROPRIETARY"/>
									</type>
								</part>
								<part>
									<part value="75 mg"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="220000000004"/>
										</coding>
										<text value="Strength part"/>
									</type>
								</part>
								<part>
									<part value="CAPSULE"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C25158"/>
											<display value="Pharmaceutical dose form part"/>
										</coding>
									</type>
								</part>
								<usage>
									<country>
										<coding>
											<system value="urn:iso:std:iso:3166"/>
											<code value="US"/>
											<display value="United States of America"/>
										</coding>
									</country>
									<language>
										<coding>
											<system value="urn:ietf:bcp:47"/>
											<code value="en"/>
										</coding>
									</language>
								</usage>
							</name>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C25391"/>
											<display value="ANALYSIS"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/618054084"/>
								</organization>
								<organization>
									<reference value="Organization/985052076"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
								<organization>
									<reference value="Organization/936889401"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C43360"/>
											<display value="MANUFACTURE"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/985052076"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
								<organization>
									<reference value="Organization/936889401"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C84731"/>
											<display value="PACK"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/618054084"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C84732"/>
											<display value="LABEL"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/134489525"/>
								</organization>
							</operation>
						</MedicinalProductDefinition>
					</resource>
				</entry>
				<entry>
					<fullUrl value="http://hl7.org/fhir/MedicinalProductDefinition/MPDPALBOCICLIB100"/>
					<resource>
						<MedicinalProductDefinition>
							<id value="MPDPALBOCICLIB100"/>
							<meta>
								<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi|1.0.0"/>
							</meta>
							<text>
								<status value="generated"/>
								<div xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
			MPDPALBOCICLIB100 <br/>
								</div>
							</text>
							<identifier>
								<system value="http://hl7.org/fhir/sid/ndc"/>
								<value value="0069-0188"/>
							</identifier>
							<type>
								<coding>
									<system value="http://ncit.nci.nih.gov"/>
									<code value="C121840"/>
									<display value="Approved for Human Use Product"/>
								</coding>
							</type>
							<domain>
								<coding>
									<system value="http://ncit.nci.nih.gov"/>
									<code value="C14225"/>
									<display value="Human"/>
								</coding>
							</domain>
							<version value="1"/>
							<status>
								<coding>
									<system value="http://hl7.org/fhir/publication-status"/>
									<code value="active"/>
									<display value="Active"/>
								</coding>
							</status>
							<statusDate value="2020-03-30"/>
							<route>
								<coding>
									<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
									<code value="C38288"/>
									<display value="ORAL"/>
								</coding>
							</route>
							<marketingStatus>
								<status>
									<!-- coding>
			<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses"/>
			<code value="active"/>
			</coding -->
									<text value="active"/>
								</status>
								<dateRange>
									<start value="2015-02-03"/>
								</dateRange>
							</marketingStatus>
							<name>
								<productName value="IBRANCE® (palbociclib) tablets - 100 mg"/>
								<part>
									<part value="palbociclib"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C71898"/>
										</coding>
										<text value="Proprietary Name"/>
									</type>
								</part>
								<part>
									<part value="palbociclib"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C3273150"/>
										</coding>
										<text value="NONPROPRIETARY"/>
									</type>
								</part>
								<part>
									<part value="100 mg"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="220000000004"/>
										</coding>
										<text value="Strength part"/>
									</type>
								</part>
								<part>
									<part value="CAPSULE"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C25158"/>
											<display value="Pharmaceutical dose form part"/>
										</coding>
									</type>
								</part>
								<usage>
									<country>
										<coding>
											<system value="urn:iso:std:iso:3166"/>
											<code value="US"/>
											<display value="United States of America"/>
										</coding>
									</country>
									<language>
										<coding>
											<system value="urn:ietf:bcp:47"/>
											<code value="en"/>
										</coding>
									</language>
								</usage>
							</name>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C25391"/>
											<display value="ANALYSIS"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/618054084"/>
								</organization>
								<organization>
									<reference value="Organization/985052076"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
								<organization>
									<reference value="Organization/936889401"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C43360"/>
											<display value="MANUFACTURE"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/985052076"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
								<organization>
									<reference value="Organization/936889401"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C84731"/>
											<display value="PACK"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/618054084"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C84732"/>
											<display value="LABEL"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/134489525"/>
								</organization>
							</operation>
						</MedicinalProductDefinition>
					</resource>
				</entry>
				<entry>
					<fullUrl value="http://hl7.org/fhir/MedicinalProductDefinition/MPDPALBOCICLIB125"/>
					<resource>
						<MedicinalProductDefinition>
							<id value="MPDPALBOCICLIB125"/>
							<meta>
								<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi|1.0.0"/>
							</meta>
							<text>
								<status value="generated"/>
								<div xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
			MPDPALBOCICLIB125 <br/>
								</div>
							</text>
							<identifier>
								<system value="http://hl7.org/fhir/sid/ndc"/>
								<value value="0069-0189"/>
							</identifier>
							<type>
								<coding>
									<system value="http://ncit.nci.nih.gov"/>
									<code value="C121840"/>
									<display value="Approved for Human Use Product"/>
								</coding>
							</type>
							<domain>
								<coding>
									<system value="http://ncit.nci.nih.gov"/>
									<code value="C14225"/>
									<display value="Human"/>
								</coding>
							</domain>
							<version value="1"/>
							<status>
								<coding>
									<system value="http://hl7.org/fhir/publication-status"/>
									<code value="active"/>
									<display value="Active"/>
								</coding>
							</status>
							<statusDate value="2020-03-30"/>
							<route>
								<coding>
									<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
									<code value="C38288"/>
									<display value="ORAL"/>
								</coding>
							</route>
							<marketingStatus>
								<status>
									<!-- coding>
			<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses"/>
			<code value="active"/>
			</coding -->
									<text value="active"/>
								</status>
								<dateRange>
									<start value="2015-02-03"/>
								</dateRange>
							</marketingStatus>
							<name>
								<productName value="IBRANCE® (palbociclib) tablets - 125 mg"/>
								<part>
									<part value="palbociclib"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C71898"/>
										</coding>
										<text value="Proprietary Name"/>
									</type>
								</part>
								<part>
									<part value="palbociclib"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C3273150"/>
										</coding>
										<text value="NONPROPRIETARY"/>
									</type>
								</part>
								<part>
									<part value="125 mg"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="220000000004"/>
										</coding>
										<text value="Strength part"/>
									</type>
								</part>
								<part>
									<part value="CAPSULE"/>
									<type>
										<coding>
											<system value="http://ncit.nci.nih.gov"/>
											<code value="C25158"/>
											<display value="Pharmaceutical dose form part"/>
										</coding>
									</type>
								</part>
								<usage>
									<country>
										<coding>
											<system value="urn:iso:std:iso:3166"/>
											<code value="US"/>
											<display value="United States of America"/>
										</coding>
									</country>
									<language>
										<coding>
											<system value="urn:ietf:bcp:47"/>
											<code value="en"/>
										</coding>
									</language>
								</usage>
							</name>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C25391"/>
											<display value="ANALYSIS"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/618054084"/>
								</organization>
								<organization>
									<reference value="Organization/985052076"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
								<organization>
									<reference value="Organization/936889401"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C43360"/>
											<display value="MANUFACTURE"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/985052076"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
								<organization>
									<reference value="Organization/936889401"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C84731"/>
											<display value="PACK"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/618054084"/>
								</organization>
								<organization>
									<reference value="Organization/341970073"/>
								</organization>
							</operation>
							<operation>
								<type>
									<concept>
										<coding>
											<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
											<code value="C84732"/>
											<display value="LABEL"/>
										</coding>
									</concept>
								</type>
								<organization>
									<reference value="Organization/134489525"/>
								</organization>
							</operation>
						</MedicinalProductDefinition>
					</resource>
				</entry>
			</Bundle>
		</resource>
	</entry>
</Bundle>
